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    Introduction 
 
The publication of a study guide on hematology is 
conditioned by the increasing prevalence of blood system 
diseases. This situation is associated with certain 
environmental changes in Ukraine, the negative impact of 
environmental factors on the human body such as ionizing 
radiation and chemicals that are widely used both in agriculture 
and food industry. 
The manual highlights the current views on the 
etiology, pathogenesis, clinic, diagnosis, differential diagnosis 
and treatment of blood disorders. Considerable attention is paid 
to anemia, since it is the most common syndrome in the 
practice of doctors of various specialties. 
Significant progress has been made in the diagnosis and 
treatment of hemoblastoses, which is also reflected in this 
manual. 
The release of this study guide is determined by the lack 
of awareness and alertness of the students and general 
practitioners in the diagnosis and treatment of hematological 
diseases, lack of textbooks devoted to this branch of medicine. 
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Section I.  ANEMIAS 
 
Anemia is a decrease in the number of red blood cells 
(RBCs), hematocrit, or hemoglobin (Hb) level in the blood. 
The RBC mass represents the balance between production 
and destruction or loss of RBCs.  
Anemia is a condition developed when your blood lacks 
enough healthy RBCs. These cells are the main transporters of 
oxygen into organs. If RBCs are also deficient in Hb, then your 
body isn't getting enough oxygen. Anemia is the most common 
blood condition in the United States. It affects about 3.5 
million Americans. Women and people with chronic diseases 
are refered to increased risk of anemia (Tables 1, 2, and 3).     
The three main causes of anemia are:  
1. Blood loss 
2. Deficient erythropoiesis 
3. Excessive hemolysis (RBC destruction).  
Table 1 ─ Classification of anemia by cause 
 
Mechanism Examples 
Blood loss   
Acute  
 
- gastrointestinal (GI) bleeding 
- Injuries 
- Childbirth 
- Surgery 
Chronic   
                    
 
- Bladder tumors 
- Cancer or polyps in gastrointestinal tract 
- Heavy menstrual bleeding 
- Kidney tumors 
- Ulcers in the stomach or small intestine 
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Table 2 ─ Deficient erythropoiesis 
 
Mechanism Examples 
Microcytiс 
 
- Iron deficiency 
- Iron-transport deficiency 
- Defective iron utilization 
- Defective iron reutilization  
- Thalassemias (also classified 
under excessive hemolysis due 
to intrinsic RBC defects) 
Normocytic- 
Normochromic  
 
- Aplastic anemia 
- Hypoproliferation 
- Chronic kidney disease 
- Endocrine disorders (thyroid, 
pituitary) 
- Protein depletion 
- Myelodysplasia 
- Myelophthisis  
Macrocytic  
 
- Copper deficiency  
- Folate deficiency  
- Vitamin B12, Vitamin C 
deficiency 
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Table 3 ─ Excessive hemolysis due to extrinsic RBC defects  
 
Mechanism Examples 
Reticuloendothelial 
hyperactivity 
with splenomegaly  
 
- Hypersplenism  
 
Immunologic 
abnormalities 
 
- Autoimmune hemolysis 
- Cold antibody hemolysis 
(paroxysmal cold 
hemoglobinuria) 
- Warm antibody hemolysis 
- Isoimmune (isoagglutinin) 
hemolysis  
Mechanical injury  
 
- Infection 
- Trauma 
Membrane alterations, 
acquired 
- Hypophosphatemia 
- Paroxysmal nocturnal 
hemoglobinuria 
- Stomatocytosis 
Membrane alterations, 
congenital 
- Membrane alterations, 
congenital 
Metabolic disorders 
(inherited enzyme 
deficiencies)  
- Embden-Meyerhof pathway 
defects 
- glucose-6-phosphate 
dehydro-genase (G-6-PD) 
deficiency  
Hemoglobinopathies - HbC, HbE, and HbS/C 
diseases 
- Hb S─β-thalassemia disease 
- Sickle cell disease (Hb S) 
- Thalassemias (β, β-δ, and α) 
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1.1. IRON DEFICIENCY ANEMIA  
(ANEMIA OF CHRONIC BLOOD LOSS. 
CHLOROSIS) 
 
Iron deficiency is the most common cause of anemia and it 
is usually a result of blood loss. Symptoms are usually 
nonspecific. RBCs tend to be microcytic and hypochromic, and 
iron stores are low as shown by low serum ferritin and low 
serum iron levels with high serum total iron binding capacity. 
If the diagnosis is made, occult blood loss is suspected. 
Treatment involves iron replacement and treatment of the cause 
of blood loss. 
Pathophysiology 
Iron deficiency anemia (IDA) occurs when your body 
doesn't have enough iron. Iron is important because it helps 
you get enough oxygen throughout your body. Your body uses 
iron for making Hb. Hb is a part of your red blood cells. Hb 
carries oxygen through your body. If you do not have enough 
iron, your body makes fewer and smaller RBCs. Therefore 
your body has less Hb, and you cannot get enough oxygen. 
Iron is distributed in active metabolic and storage pools. 
Total body iron is about 3.5 g in healthy men and 2.5 g − in 
women; the difference is related to women's smaller body size, 
lower androgen levels, and dearth of stored iron because of 
iron loss during menses and pregnancy.  
The iron in the body of the average man is distributed as 
follows:   
  - Hb, 2100 mg;  
- ferritin, 700 mg (in cells and plasma); 
- hemosiderin, 300 mg (in cells);  
- myoglobin, 200 mg; 
- tissue (heme and nonheme) enzymes, 150 mg; 
- transport-iron compartment, 3 mg. 
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Iron Absorption 
Iron is absorbed in the duodenum and upper jejunum. 
Absorbtion of iron is determined by the type of iron molecule. 
Iron absorbtion is the best when food contains heme iron 
(meat). Dietary nonheme iron must be reduced. Nonheme iron 
absorption is reduced by other food items (vegetable fiber 
phytates and polyphenols; tea tannates, including 
phosphoproteins; bran) and certain antibiotics (tetracycline). 
Only ascorbic acid is the common food element to increase 
nonheme iron absorption. 
The average American diet, which contains 6 mg of 
elemental iron/kcal of food, is adequate for iron homeostasis. 
Adults absorb only 1 mg of iron, which is the approximate 
amount lost daily by cell desquamation from the skin and 
intestines from 15 mg/day of dietary iron. Children have a 
greater need for iron. 
Iron Transport and Usage 
Iron from intestinal mucosal cells is transferred to 
transferrin, an iron-transport protein synthesized in the liver; 
transferrin can transport iron from cells (intestinal, 
macrophages) to specific receptors on erythroblasts, placental 
cells, and liver cells.  
For synthesis of heme, transferrin transports iron to the 
erythroblast mitochondria, which insert the iron into 
protoporphyrin for heme formation. 
Transferrin (plasma half-life, 8 days) is extruded for 
reutilization.  
Synthesis of transferrin increases with iron deficiency but 
decreases with any type of chronic disease. 
Iron Storage and Recycling 
Iron not used for erythropoiesis is transferred by transferrin, 
an iron-transporting protein, to the storage pool where it is 
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stored in 2 forms: ferritin and hemosiderin. The most important 
is ferritin (a heterogeneous group of proteins surrounding an 
iron core), which is a soluble and active storage fraction 
located in the liver (in hepatocytes), bone marrow, and spleen 
(in macrophages); in RBCs; and in serum.  
Iron stored in ferritin is readily available for any body 
requirement. Circulating (serum) ferritin level parallels the size 
of the body stores (1 ng/mL=8 mg of iron in the storage pool). 
The second storage pool of iron is situated in hemosiderin, 
which is relatively insoluble and is stored primarily in the liver 
(in Kupffer cells) and in the marrow (in macrophages). 
The body recycles and conserves iron because its absorption 
is limited. Transferrin grasps and recycles available iron from 
aging RBCs undergoing phagocytosis by mononuclear 
phagocytes. This mechanism provides about 97% of the daily 
iron need (about 25 mg of iron). With aging, iron stores tend to 
increase because of slow iron elimination. 
 
Etiology 
IDA is caused by low levels of iron in the body. Dietary iron 
barely meets the daily requirement for most people because of 
poor absorbtion of iron.  However, even modest losses, 
increased requirements, or decreased intake readily produces 
iron deficiency. Blood loss is almost always the cause, further 
more it  is usually chronic occult bleeding, from the GI tract 
(this bleeding may be caused by such problems as ulcers, 
hemorrhoids, or cancer; this bleeding can also happen with 
regular aspirin use); heavy menstrual bleeding, premenopausal 
period in women. Bleeding inside the body is the most 
common cause of iron deficiency anemia in men and 
postmenopausal women.  
Deficiency of vitamin C can contribute to iron deficiency 
anemia by producing capillary fragility, hemolysis, and 
bleeding. 
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Iron requirement is increased (during adolescence, when 
rapid growth requires a large iron intake; during pregnancy; 
lactation). 
Decreased iron absorption can be the result of gastrectomy 
and   malabsorption syndromes of upper small-intestine. 
Rarely, absorption is decreased by dietary deprivation from 
undernutrition, when patients do not get enough iron from 
food. It can happen in people who need a lot of iron: children 
from birth to age 2, during adolescence, and pregnant women. 
Symptoms and Signs 
Mild IDA may not cause the noticeable symptoms. Most 
symptoms of iron deficiency are due to anemia. Such 
symptoms include fatigue, loss of stamina, shortness of breath 
during exercise, weakness, dizziness, irritability, impaired 
concentration, headache and pallor. Symptoms of severe 
deficiency include an abnormal craving for eating substances 
that are not food (pica), in particular, ice, dirt, or paint. 
Glossitis, cheilosis, concave nails (koilonychia), and, rarely, 
dysphagia are caused by a postcricoid esophageal web 
(Plummer-Vinson syndrome). Other signs may include rapid 
heartbeat; brittle fingernails; cracked lips; smooth, sore tongue; 
muscle pain during exercise; and difficulty swallowing. 
Babies and young children with IDA may not grow as 
expected and may have delays in skills such as walking and 
talking. Children may be fussy, irritable and have a short 
attention span. These problems are usually gone away when 
deficiency is treated. If it is not treated, mental and behavioral 
problems will become permanent. 
Diagnosis 
RBC, serum iron and iron-binding capacity test, serum 
ferritin test (rarely), and bone marrow examination 
Normal serum iron level ranges from 75 to 150 μg/dL                
(13−27 μmol/L) for men and from 60 to 140 μg/dL                        
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(11−25 μmol/L) for women; total iron-binding capacity is            
250−450 μg/dL (45 − 81 μmol/L).  
Serum transferrin receptor levels reflect the quantity of RBC 
precursors available for active proliferation; levels are sensitive 
and specific. The normal levels are 3.0−8.5 mg/mL. Levels 
increase in early iron deficiency and with increased 
erythropoiesis (Table 4). 
Serum ferritin levels closely correlate with total body iron 
stores. Most laboratories range the normal ferritin 
concentration from 30 to 300 ng/mL, and the mean serrum 
ferritin concentration is 88 in men and 49 in women. Low 
levels (<2 ng/mL) are specific for iron deficiency.  
Stages of iron deficiency: Laboratory test results help stage 
iron deficiency anemia (Table 5). 
1. Stage 1 is characterized by decreased bone marrow iron 
stores. Hb and serum iron remain normal, but serum ferritin 
level falls to <20 ng/mL. The compensatory increase of iron 
absorption causes the increase of iron-binding capacity 
(transferrin level). 
2. During stage 2, erythropoiesis is impaired. Although the 
transferrin level is increased, the serum iron level decreases; 
transferrin saturation decreases. Erythropoiesis is impaired 
when serum iron falls to <50 μg/dL (<9 μmol/L) and 
transferrin saturation – to <16%. The serum ferritin receptor 
level rises (>8.5 mg/L). 
3. During stage 3, anemia with normal-appearing RBCs and 
indices develops. 
4. During stage 4, microcytosis and hypochromia develops. 
5. During stage 5, iron deficiency affects tissues; symptoms 
and signs of IDA. 
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Table 4 − Differential diagnosis of microcytic anemia due to 
decreased RBC production 
 
Diagnostics 
Criteria 
Iron 
Deficiency 
Iron-
Transport 
Deficiency 
 
Sideroblastic 
Iron 
Utilizatin 
Iron 
Reuti-
lization 
Peripheral smear 
Microcytosis (M) vs 
hypochromia (H) 
M > H M > H M > H , may 
be 
normocytic 
 
M > H 
Polychromatophilic 
targeted cells  
Absent Absent Present Absent 
Stippled RBCs Absent Absent Present 
 
Absent 
RBCs 
RBC distribution 
width 
↑ ↑ ↑ Normal 
Serum iron 
Serum iron: iron-
binding capacity  
↓:↑ ↓:↑ ↑:Normal ↓:↑ 
% Saturation of 
transferrin  
< 10 0 > 50 > 10 
Serum ferritin 
Normal 30–300 
ng/mL)  
< 12 No data 
available 
> 400 30–400 
Bone marrow 
RBC: granulocyte 
ratio (normal, 1:3–1:5)  
1:1–1:2 1:1–1:2 1:1–5:1 1:1–1:2 
   Marrow iron  Absent Present ↑ Present 
Ringed sideroblasts Absent Absent Present Absent 
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Table 5 − Differential diagnosis of hypochromic anemias 
 
Etiology or Type Morphologic Changes Special Features 
Blood loss, 
acute 
Normocytic 
normochromic, with 
polychromatophilia; 
hyperplastic marrow 
If severe, possible nucleated; 
RBCs and left shift of white 
blood cells (WBCs); 
   leukocytosis; 
   thrombocytosis 
Blood loss, 
chronic 
Same as iron deficiency Same as iron deficiency 
Iron deficiency Microcytic, with 
anisocytosis and 
   poikilocytosis; 
reticulocytopenia; 
hyperplastic marrow, 
with delayed 
hemoglobination 
Possible achlorhydria, 
smooth tongue, and spoon 
nails; 
absent stainable marrow iron; 
   low serum iron; 
increased total iron-binding 
   capacity; 
low serum and RBC ferritin 
Marrow failure Normochromic-
normocytic (may 
   be macrocytic); 
reticulocytopenia; 
failed bone marrow 
aspiration (often) 
or evident hypoplasia of 
erythroid series or all 
elements 
 
Idiopathic (> 50%) but 
secondary to exposure to 
drugs or toxic chemicals 
(chloramphenicol, 
quinacrine, hydantoins, 
   insecticides) 
Bone marrow 
replacement 
(myelophthisis) 
Anisocytosis and 
poikilocytosis; 
nucleated RBCs; 
early granulocyte 
precursors; 
bone marrow aspiration 
may fail or may show 
leukemia, myeloma, or 
   metastatic cells 
Bone marrow infiltration 
with infectious granulomas, 
tumors, fibrosis, or lipid 
histiocytosis; 
possible hepatomegaly and 
   splenomegaly; 
possible bony changes; 
radioiron uptake greater over 
spleen and liver than over 
sacrum 
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Table 5 (cont.) 
 
Etiology or 
Type 
Morphologic Changes Special Features 
 
Thalassemia 
   Microcytic; 
   thin cells; 
   target cells; 
basophilic stippling; 
anisocytosis and 
poikilocytosis; 
nucleated RBCs in 
homozygotes 
Decreased RBC fragility; 
elevated Hb A2 and Hb F 
(often); 
mediterranean ancestry 
(common); 
anemic homozygotes from 
infancy; 
   splenomegaly; 
bone changes on X-ray 
Sideroblastic 
anemia 
Usually hypochromic 
but dimorphic with 
normocytes and 
macrocytes; 
hyperplastic marrow, 
with delayed 
hemoglobination; 
ringed sideroblasts 
Inborn or acquired 
metabolic defect; 
stainable biopsy in bone 
marrow (plentiful); 
response to vitamin B6 
administration (rare); 
may be a part of 
myelodysplastic syndrome 
 
Treatment 
Patients will benefit from iron pills if they take them with 
vitamin C or drink orange juice. Do not take your iron pills 
with milk, caffeine, high-fiber foods, or antacids. Patients with 
IDA should take oral supplemental iron and parenteral iron 
rarely. Iron therapy without pursuit of the cause is a poor 
practice; the bleeding site should be sought out even in cases of 
mild anemia. Iron can be provided by various iron salts 
(ferrous sulfate, ferrous gluconate, ferrous fumarate) or 
saccharated iron po 30 min before meals (food or antacids may 
reduce absorption). 
A typical initial dose is 100 mg of elemental iron (similar to 
325 mg of ferrous sulfate) given 1 or 2 times/day.  Parenteral 
 15 
iron causes the same therapeutic response as oral iron but can 
cause such adverse effects as anaphylactoid reactions, serum 
sickness, thrombophlebitis, and pain. It is reserved for patients 
who do not tolerate or do not take oral iron, or for patients who 
steadily lose large amounts of blood because of capillary or 
vascular disorders (hereditary hemorrhagic telangiectasia). The 
dose of parenteral iron is determined by a hematologist. Oral or 
parenteral iron therapy should continue for ≥ 6 months after 
correction of Hb levels to replenish tissue stores. 
The response to treatment is assessed by serial Hb 
measurements until normal RBC values are achieved. Hb rises 
little for 2 week but then rises 0.7 to 1 g/wk until near normal, 
at which time rate of increase tapers. Anemia should be 
corrected during 2 months. A subnormal response suggests 
continued hemorrhage, underlying infection or cancer, 
insufficient iron intake, or, very rarely, malabsorption of oral 
iron. 
Patients should not take iron pills: within 2 hours of taking 
antacids or tetracycline (an antibiotic); with certain foods, 
chemicals, and nutrients such as tea, coffee, chocolate, and 
other foods or beverages high in caffeine; milk and other 
calcium-rich foods or supplements; high-fiber foods such as 
bran, whole grains, nuts, and raw green vegetables. 
For some people, iron supplements can cause stomach 
discomfort, nausea, diarrhea, constipation, and black (tar) 
colored stool. Iron is absorbed the best if taken on an empty 
stomach. But if patients have  stomach problems, they may 
need to take the pills with food.  
 
Prevention of IDA 
A patient can prevent anemia by eating foods that include 
good sourses of iron every day. Iron-rich products include 
meats, vegetables, and whole grains such as iron-fortified 
cereals. In order to prevent IDA in babies and children, they 
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should be fed by certain food for infants, parents should ensure 
that children reseive sufficient amounts of iron with food. IDA 
in pregnant women may be prevented by taking prenatal 
vitamins. A doctor should prescribe prenatal vitamins with iron 
for pregnant women. A doctor should also test women’s blood 
to see if she has an anemia dignosis. If she has IDA, she will 
take a higher-dose iron pills. The drug regime depends on the 
seriousness of anemia. 
A diet plan №15 with high levels of proteins, vitamins, iron 
and microelements is prescribed for iron-deficient patients.  
The causal therapy for IDA is radical. It is necessary to 
eliminate the cause of IDA: to treate enteritis, to do surgery for 
fibromioma, intestinal tumors and others. 
The pathogenetic therapy is prescribed for patients with 
difficult-to-treate basic deseases.  
     There are some rules for successful treatment of IDA and 
latent iron deficiency. The diet is expedient, but it is not 
enough for full elimination of iron deficiency.  The 
consumption of half-baked liver may be is the cause of 
salmonellosis and intestinal worms. Eating too much carrot 
may cause carotene jaundice. Meat products, especially beef, 
are the most important food sourses of heme iron (Fe+2) that is 
readily absorbed by the body. There is non-heme iron (Fe+3) in 
products of plant origin. The absorption of non-heme iron from 
plant foods is insufficient. Non-heme iron (Fe+3) needs an 
acidic component to help convert it to heme form (Fe+2) to be 
easily absorbed. 
      Blood transfusion is prescribed only for patients with vital 
indications (Hb<30 g/l, hemodynamic disorders, urgent birth, 
surgeries). There is a danger of contracting serum hepatitis, 
inflectional mononucleosis, venereal diseases, and acquired 
immunodeficiency syndrome. 
       Such medications as Aktiferrin, Ferrogradument, Heferol, 
Conferon, Sorbіfer Durules, Ranferon-12, Tardyferon are the 
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main drugs for iron replacement therapy in IDA. The 
prescription of vitamin B12 and folic acid without special 
indication is not recommended. 
       Oral iron supplements are used par excellence. The 
medicines with iron should be taken before a meal for better 
absorption. Meat products, especially beef, are the most 
important food sourses of heme iron (Fe+2) that is readily 
absorbed by the body. 
      There are a lot of adverse effects after parenteral 
introduction of medicines (e.g., Ferrum Lek), such as allergic 
reactions, anaphylactic shock, phlebitis, infiltration, abscess, 
siderosis of internal organs, sarcoma of soft tissues. Parenteral 
iron administration is prescribed according to such indications 
as poor iron absorbtion, gastrectomy, enteritis with 
malabsorption syndrome, bowel resection, ineffective primary 
treatment, or acute ulcer disease. 
      It is neseccary to continue therapy with iron medicines 
during the next few months after normalization of hemoglobin 
and erythrocyte levels to replenish iron stores. Doses and 
duration of treatment are individual. 
      There are some stages for IDA treatment.      
      The first step is the normalization of glycated hemoglobin 
levels in the blood. It is necessary to prescribe medicines with 
iron in terms of recovered iron (Fe+2) during 1−2 months. The 
daіly dose is 200−300 mg. For example, we can prescribe 1 
tablet of Tardyferon (contains 100 mg of Fe+2) 2 or 3 times a 
day considering the seriousness of anemia.  
      The second step is the normalization of iron reserves in the 
body. Iron medication is prescribed in a half treatment dose (1 
tablet of Tardyferon once a day) to be taken during 1−2 
months. 
      The third step is the preventive prescribtion of iron 
medicines in full treatment dose during one week every month 
for patients with bleeding or a suspicion of it: women with long 
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(more than 5 days) and excessive menses, patients with chronic 
deseases and bleeding, severy diseases, such as unspecific ulcer 
colitis, diverticulitis, hemorrhoids and others.  
     Higher doses of iron can cause stomach and intestinal 
problems, liver failure, dangerously low blood pressure and 
death. This is connected with the ability of Fe+3 to dissociate 
and excrete iron ions. Iron ions can denature proteins of 
mucous membrane. This process results in discomfort, nausea, 
diarrhea, and constipation. Iron binds to hydrogen sulfide that 
may cause rapid peristalsis or constipation.  
The independent iron radicals can enhance the process of 
lipid peroxidation which is characteristic of the hypoxic state, 
including antioxidants to prevent reactions with independent 
radicals. 
Introduction of such antioxidants and stimulators of 
absorption as vitamin E, ascorbic acid, glucose, 
fruktozodyfosfat, succinic or citric acid is necessary for 
portability improvement of iron medicine.  
The portability of medicines is individual in clinical 
practice. The selection of optimal medicines according to the 
portability is empirical. 
The positive effect is achieved by the increase of Hb 
concentration per 1 g/l, in general, during one day (20 g/l 
during 3 weeks). The greatest increase occurs in severe anemia. 
The earliest signs of positive treatment effect appear with a 
higher reticulocyte count (the increase of reticulocyte count 
quantity on the 4−7 day after the first intake of iron-containing 
drug, compared to initial count, 2−10 times). 
 
1.2. VITAMIN B12 DEFICIENCY ANEMIA 
Deficiency of vitamin B12 causes megaloblastic anemia, 
damage to the white matter of the spinal cord and brain, and 
peripheral neuropathy. 
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Diagnosis is usually made by measuring the level of vitamin 
B12 in serum.  
The Schilling test is used to determine whether body absorbs 
vitamin B12 normally. Treatment of anemia consists of oral or 
parenteral introduction of vitamin B12 (Table 6). 
Table 6 − Causes of vitamin B12 deficiency 
 
Cause Source 
Inadequate diet - Vegan diet; 
- Breastfeeding of infants by vegan 
mothers; 
- Fad diets  
Impaired 
absorption 
- Lack of intrinsic factor (due to 
pernicious anemia, destruction of gastric 
mucosa, gastric surgery, or gastric bypass 
surgery); 
- Intrinsic factor inhibition; 
- Decreased acid secretion; 
- Small-bowel disorders (inflammatory 
bowel disease, sprue, cancer, biliary or 
pancreatic disorders); 
- Competition for vitamin B12 (in fish 
tapeworm infestation or blind loop 
syndrome); 
- acquired immune deficiency syndrome  
Inadequate 
utilization 
- Enzyme deficiencies 
- Liver disorders 
- Transport protein abnormality  
   Drugs - Antacids; 
- Metformin; 
- Nitrous oxide  
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Pathophysiology 
Cobalamin is a general form of a compound for biological 
activity of vitamin B12. This compound is involved into 
metabolism of every cell of the human body: nucleic acid 
degradation, methyl compounds transfer, myelin synthesis and 
maintenance. They are necessary for the formation of normal 
RBCs. Food-bound vitamin B12 is released in the stomach's 
acid environment and is bound to R protein (haptocorrin). 
Pancreatic enzymes cleave this B12 complex (B12-R 
protein) in the small intestine. After cleavage, intrinsic factor, 
secreted by parietal cells in the gastric mucosa, binds with 
vitamin B12. Intrinsic factor is required for absorption of 
vitamin B12, which takes place in the terminal ileum. Vitamin 
B12 in plasma is bound to transcobalamins I and II. 
Transcobalamin II is responsible for delivering vitamin B12 to 
the tissues. The liver stores large amounts of vitamin B12. 
Enterohepatic reabsorption helps to retain vitamin B12. Liver 
vitamin B12 stores can normally sustain physiologic needs for 
3 to 5 years if B12 intake stops (in people who become vegans) 
and for months to 1 year if enterohepatic reabsorption capacity 
is absent. B12 is required by enzymes for two reactions: the 
conversion of methylmalonyl-CoA to succinyl-CoA and the 
conversion of homocysteine to methionine. In the second 
reaction, the methyl group of 5-methyltetrahydrofolate is 
transferred into homocysteine for production of 
tetrahydrofolate and methionine. This reaction is catalysed by 
enzyme methionine synthase of B12 as an essential cofactor. 
During B12 deficiency, this reaction cannot proceed, which 
leads to the accumulation of 5-methyltetrahydrofolate. This 
accumulation depletes the other types of folate that are required 
for purine and thymidylate synthesis, which are required for the 
synthesis of deoxyribonucleic acid (DNA). As a result of 
inhibition of DNA synthesis in RBCs, there is the formation of 
large, fragile megaloblastic erythrocytes. The neurological 
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aspects of the disease are thought to arise from the 
accumulation of methylmalonyl-CoA due to the requirement of 
B12 as a cofactor of the enzyme methylmalonyl-CoA mutase. 
Pernicious Anemia 
Pernicious anemia (PA) (also known as Biermer’s 
anemia, Addison’s anemia, or Addison-Biermer’s anemia) 
is a type of megaloblastic anemia, resulting from vitamin B12 
deficiency. Impared intrinsic factor production can occur in 
adults due to autoimmune destruction of parietal cells, which 
secret intrinsic factor. Patients with PA, mostly young adults,  
belong to the increased risk group of gastric and other GI 
cancers. 
SYMPTOMS AND SIGNS OF VITAMIN B12 
DEFICIENCY ANEMIA 
Vitamin B12 deficiency is usually assosiated with various 
hematological, gastrointestinal and neuropsychiatric disorders. 
There are many signs and symptoms that indicate anemia. 
However, in 20% of cobalamin deficiency cases, anemia is not 
observed. 
Typical symptoms of B12 deficiency anemia: 
1. Anemia: Anemia may cause fatigue,  tachycardia (rapid 
heartbeat) and cardiac murmurs, along with a yellow waxy 
pallor, low blood pressure, high blood pressure and 
shortness of breath (known as "the sighs"). In severe cases, 
the anemia is able to cause the evidence of congestive heart 
failure. Other hematological symptoms are cytopenias, 
intramedullary hemolysis with splenomegaly and 
hepatomegaly, and pseudothrombotic microangiopathy. 
2.  Gastroenterological disorders: Gastroenterological 
symptoms may include dyspepsia, nausea, heartburn, 
diarrhoea, weight loss, and poorly localized neuropathic 
abdominal pain also may occur. Hunter’s glossitis (swollen 
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red tongue), atrophy of the lingual papillae,
 
and angular 
cheilitis, usually described as burning of the tongue, are 
uncommon. Sometimes there appear dehydrated/cracked 
and pale lips, dark circles around the eyes (look of 
exhaustion), brittle nails and hair thinning with early 
greying. 
3. Neurological disorders: They mostly affect white matter 
of the brain and spinal cord. Demyelinating or axonal 
peripheral neuropathies can occur. The symptoms may 
include difficulties in proprioception (called memory 
changes), mild cognitive impairment (including difficulty 
concentrating and sluggish responses, colloquially referred 
to a brain fog), impaired urination, loss of sensation in the 
feet, unsteady gait (walking), muscle weakness and 
clumsiness, and the symptoms of neuropaty. At the first 
stages, we observe decreased position and vibratory 
sensations in the extremities, which are accompanied by 
mild to moderate weakness and hyporeflexia. A 
complication of severe chronic B12 deficiency anemia 
results in subacute combined degeneration of spinal cord, 
which leads to distal sensory loss (posterior column), 
absent ankle reflex, increased knee reflex response, and the 
extensor plantar response. The symptoms of the final stages 
are spasticity, the extensor plantar responses, the greater 
loss of position and vibratory sensation of the lower 
extremities, and ataxia. 
 
Diagnosis 
Hematological, gastrointestinal and medical disorders: A 
clinical blood test reveals the symptoms of megaloblastic 
anemia through a standard complete blood count. The 
evaluation of the mean corpuscular volume (MCV) as well as 
the mean corpuscular Hb concentration (MCHC) can help spot 
hyperchromic anemia.  
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PA is defined by a high MCV and a normal MCHC (that is, 
it is a macrocytic, normochromic anemia). Ovalocytes are also 
typically seen on the blood smear, and a pathognomonic 
feature of megaloblastic anemias (included PA and others) is 
hypersegmented neutrophils. A vitamin B12 deficiency is 
defined as being vitamin B12 serum levels of under 200 
pg/mL (<145 pmol/L). The Schilling test is used to distinguish 
PA from other causes of B12 deficiency (intestinal 
malabsorption). The classic test for PA, the Schilling test, is no 
longer widely used, as more efficient methods   (in addition to 
the difficulties with radiolabelled agent) are available. The 
other main diagnostic feature of serum vitamin B12 low levels 
cannot be relied upon as patients can have high levels of serum 
vitamin B12 and still have pernicious anemia. 
The methylmalonic acid test, performed on blood or urine, 
is the indication of vitamin B12 deficiency, especially if the 
B12 deficiency is mild or just beginning. The methylmalonic 
acid test is often used to clarify ambiguous vitamin B12 test 
results. The diagnosis of atrophic gastritis type A should be 
confirmed by gastroscopy and stepwise biopsy. Approximately 
90 % of individuals with PA have anti-parietal cell antibodies. 
However, only 50 % of the population with these antibodies 
has the PA. 
Treatment  
- Vitamin B12 1,000 to 2,000 mcg intramuscularly can be 
given once daily to patients who have severe B12 deficiency or 
neurologic symptoms or signs.  
- Vitamin B12 1,000 mcg intramuscularly is usually given 
once daily or every other day for several weeks until 
hematologic values have returned to normal. 
- Although hematological abnormalities are usually corrected 
within 6 weeks (reticulocyte count should have returned to 
normal within 1 week), but neurologic symptoms may take 
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much longer treatment. Neurologic symptoms that persist for 
months or years become irreversible.  
For the secondary prevention of Vitamin B12 deficiency 
anemia, patients should take regular checkups and keep up with 
cyanocobalamin injections. 
 
1.3. HEMOLYTIC ANEMIAS 
Hemolytic anemias (HA) are the group of diseases 
characterized by increased erythrocytolysis (hemolysis) which 
occurs if the rate of erythrocyte destruction is increased thereby 
decreasing erythrocyte lifespan. 
The lifespan of erythrocytes in a healthy individual is 
100−120 days. Senescent erythrocytes are subjected to 
sequestering in the spleen, liver and bone marrow. 
Erythrocytolysis causes the formation of bilirubin yellow 
pigment in blood as an indirect (unconjugated) bilirubin which 
is transported to the hepatocytes where it coalesces with 
glucuronic acid by the enzyme glucuronyltransferase. Bilirubin 
glucuronide (conjugated) exits the hepatocytes into the bile via 
the biliary ducts and, together with hepatic bile, it is excreted 
into the intestine. In case of HA, as a result of intensified 
erythrocytolysis, the lifespan of erythrocytes decreases to 
12−14 days. 
1. There are intracellular and intravascular forms of anemia 
according to mechanism of hemolysis. Intracellular 
erythrocytolysis takes place in the cells of reticulo-histiocyte 
system, mainly in the spleen, and it is accompanied by 
increased content of indirect (unconjugated with glucuronic 
acid) bilirubin in the blood, increased excretion of urobilin with 
urine and faeces, and a tendency to stone formation in the 
gallbladder and the bile ducts. In case of intravascular 
hemolysis (it takes place in the bloodstream involving 
complement), hemoglobin in high amounts enters the plasma 
and excretes with urine in an unchanged form or as 
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hemosiderin. The latter one can be deposited in the inner 
organs with subsequent development of hemosiderin. 
2. There are two causes of hemolysis, specified by erythrocytic 
(extracorpuscular) and endo-erythrocytic (corpuscular) factors. 
3. There are acute and chronic forms of hemolysis according to 
the clinical course. 
4. All HAs are divided into two big groups called inherited and 
acquired according to the origin. Hereditary HAs are the result 
of various genetic defects in the erythrocytes caused by their 
loss of functional adequacy and endurance. 
 
Hereditary HAs are subdivided into the following 
pathological forms: 
- Membranopathies (Minkowski-Chauffard microsphere-
cytosis, ovalocytosis, etc.), associated with erythrocyte 
membrane disorders caused by changes in erythrocyte shape; 
- Enzymopathies caused by deficiency of enzymatic systems in 
the erythrocytes (G-6-PD, pyruvate kinase, and glutathione 
reductase); 
- Hemoglobinopathies (thalassemia and sickle-cell anemia) 
caused by failure in Hb structure and synthesis. 
     Acquired HAs are caused by the following factors which 
contribute into erythrocytoschisis: 
- Action of antibodies (isoimmune, transimmune, 
heteroimmune and autoimmune); 
- Change in the membrane structure of erythrocytes as the 
result of somatic mutation (Marchiafava-Micheli syndrome); 
- Mechanical injury of erythrocyte membranes (valve 
prosthesis and paroxysmal nocturnal hemoglobinuria); 
- Chemical injury to erythrocytes (toxic agents – hydrazine, 
arsenic, lead, heavy metals, phenol, toluene, benzol, aniline, 
trichloroethylene, trinitrobenzol, lysol, hydrogen sulphide, 
acetic acid and other acids, copper, pesticides, etc.); 
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- Action of biological and bacterial toxins; 
- Action of parasites (malaria and toxoplasmosis). 
 
Classifications: 
1. According to the International Classification of Diseases, 
10th Revision (ICD-10) HAs are assigned the following     
ICD-10 diagnosis codes: D-55 – anemia due enzyme disorders; 
D-56 – thalassemia; D-57 – sickle-cell disorders; D-58 – other 
hereditary HA; D-59 – acquired HA. 
2. There is the classification of hemolytic anemia designed by        
A.I. Vorobiev in 1985: 
I. Hereditary HA: 
1. Caused by erythrocyte membrane damage: 
a) hereditary microspherocytosis, elliptocytosis, 
stomatocytosis, and pyropoikilocytosis; 
b) hereditary without Rh- antigens; 
c) structural failure of lipids. 
2. Caused by erythrocyte enzyme deficiencies: 
a) deficiency of G-6-PD activity; 
b) erythrocyte pyruvate kinase deficiency. 
3. Thalassemias. 
4. Caused by disorders of Hb formation: 
a) Hb carriers that change its structure in hypoxia; 
b) sickle-cell disease; 
c) carriers of abnormal stable Hb; 
d) carriers of abnormal unstable Hb. 
II. Acquired HA: 
            1. HA caused by the action of antibodies (immune): 
a) isoimmune; 
b) heteroimmune; 
c) autoimmune.  
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      2. Marchiafava-Micheli syndrome (paroxysmal 
nocturnal hemoglobinuria). 
      3. HA caused by mechanical erythrocyte 
destruction: 
a) march hemoglobinuria; 
b) mechanical hemolysis following valve and 
vessel replacement; 
c) hemolytic-uremic syndrome (HUS). 
                  4. HA caused by vitamin E deficiency. 
The most widespread anemia among hereditary HA is a 
hereditary microspherocytosis (Minkowski-Shauffard disease). 
For the first time this disease was described by Minkowski in 
1900, and for the second time – by Shauffard with more 
details. Autosomal-dominant inheritance of the disease is based 
on the genetic defect of erythrocyte membrane protein or 
spectrin. 
 
Pathogenesis 
As the result of hyperpermeability of defective membrane to 
sodium ions, there is the increase of water content in the 
erythrocytes, opposed to biconcave normal ones, that become 
spherical without deformation when pasing narrow places in 
the bloodstream. That slows down their movement in the 
spleen sinuses, partially abrupts erythrocytes with the 
following formation of microspherocytes (microspherocytosis) 
and their rapid destruction. Such erythrocytes are absorbed by 
the macrophage of the spleen. Constant hemolysis of 
erythrocytes in the spleen causes hyperplasia of splenic pulp 
cells and an increase of the organ. 
 
Signs and Simptoms 
Microspherocytosis has a typical clinical picture of HA with 
intracellular hemolysis: anemia, jaundice, and spleenomegaly. 
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Besides, there are such inherent stigmata as skeleton 
deformation (arched skull, high “Gothic” palate, broad nose 
bridge, short fingers), eyes and teeth anomaly, and otosclerosis. 
Anemia usually affects adolescents, sometimes − adults. The 
severity of anemia depends on erythrocytoschisis rate and 
recovery properties of erythropoiesis ratio. In young people, 
anemia causes disorders of mental and physical development. 
Subjectively, sick people feel considerably better when 
erythrocytes and Hb indices are lower than in IDA. On the one 
hand, the intensity of jaundice depends on the degree of 
erythrocytoschisis, on the other hand − on functional capacity 
of the liver associated with the ability to combine bilirubin and 
glucuronic acid and to excrete them together with bile. If 
hemolysis is not clinically apparent, jaundice may be absent. 
As the result of jaundice and anemia combination, the skin 
becomes lemon-colored.  
Formation of gallstones is caused by a three-fold increase in 
bilirubin level in the bile (pleiochromy).  
Cholelithiasis with a hepatic colic attack or development of 
obstructive (mechanical) jaundice is a frequent complication of 
microspherocytosis. In case of latent clinical course of 
hemolytic disease without apparent anemia and jaundice but 
with decreased lifespan of erythrocytes, increased billirubin 
level in the bile and increased stercobilinogen outflow 
dominate in the clinical picture. Some time later cholelithiasis 
may occure with such complications as cholestatic hepatitis 
and hepatocirrhosis. Splenomegaly in case of 
microspherocytosis doesn’t develop significantly. Against the 
background of chronic course of hemolytic anemia under the 
influence of any infection or concussion, hemolytic crisis with 
sudden deterioration of general state may occure with 
exacerbation symptoms (increased severity of anemia, 
jaundice, urobilinuria), and temperature rise.  
 29 
One of the most dangerous complications of HA with severe 
clinical course is hypoplastic crisis associated with temporary 
erythropoiesis insufficiency during 7−15 days. Such patients 
are in urgent need of medical care.  
 
Laboratory diagnosis includes the following key findings: 
- Degree of severity: most frequent is moderate normochromal 
anemia (Hb and erythrocyte rates decrease simultaneously). 
After hemolytic crisis anemia intensifies (Hb rates sometimes 
decrease to 20−30 g/l); 
-  Erythrocytes look like microspherocytes; 
- Reticulocytosis, most frequently moderate, reflects the degree 
of compensatory hematopoiesis in the bone marrow. It 
intensifies after hemolytic crisis and is absent after hypoplastic 
crisis: the number of  platelets and leukocytes remains the 
same, but after the crisis, leukocytosis occurs due to activated 
neutrophils, accompanied by neutrophic left shift; 
-  Bilirubinemia at the expense of unconjugated bilirubin, an 
increase of conjugated one in case of cholelithiasis. Normal 
rates are possible in case of satisfactory function of the liver 
and insignificant hemolysis (diagnosis of hemolytic anemia 
cannot be excluded); 
- Urobilinuria (the degree of manifestation also depends on the 
liver function); 
- Increase of stercobilinogen in feces (dark color of feces − 
pleioschomy); 
- Increased iron content in blood serum; 
- Myelogram shows signs of hyperplasia of the red blastema 
with erythronormoblastic reaction: the number of 
erythrokaryocytes in the bone marrow is more than 25%; in 
case of hypoplastic crisis erythroblastopenia occurs. 
- Osmotic resistance of erythrocytes decreases: the beginning 
of hemolysis with 0.75% sodium chloride, and the termination 
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of haemolysis – 0.45% (0.45−0.4 − healthy people and 0.35 − 
sick people correspondingly). 
 
Diagnosis Criteria  
Normochromal anemia, jaundice, splenomegaly, 
microspherocytes in the peripheral blood, reticulocytosis, 
reduction of osmotic fragility of erythrocytes, 
hyperbilirubinemia (with prevalence of unconjugated fraction), 
urobilinuria, large amount of stercobilin in feces, hyperplasia 
of erythroid lineage in myelogram (prevalence of erythro- and 
normoblasts). 
 
Treatment   
One of the most effective methods for hereditary 
microspherocytosis treatment is splenectomy, where 
spherocytes remain, while the anemic syndrome is suppressed. 
If there is no effect of splenectomy, it indicates inadequacy of 
the diagnosis or presence of an accessory spleen. Splenectomy 
in the pediatric age (in children younger than 10 years) 
increases the risk of infectious diseases because of inferiority 
of the immune system.  
Direct indications for splenectomy are: 
- hemolytic and hypoplastic crises; 
- pediatric anemia which can range from stable moderate to 
severe acute and unstable that negatively affects physical and 
mental development of children; 
- morbid states that are complicated by cholelithiasis with 
hepatic colic and cholestatic hepatitis (in such cases 
splenectomy is performed together with cholecyctectomy). 
In case of severe hemolytic or hypoplastic crisis, a 
transfusion of red blood cell concentrate is indicated. 
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1.3.1. HEREDITARY ENZYMOPATHY 
(FERMENTOPATHY) 
 
Etiology 
HA which is associated with the enzyme defects in 
glycolysis, pentosephosphate pathway, and glutathione 
senthetase deficiency is inherited in a recessive manner. 
 
Pathogenesis 
HA which is caused by enzyme defects in glycolysis is 
associated with the disturbance of adenosine triphosphate 
formation in the erythrocytes.  
Ionic composition in such erythrocytes changes, their vital 
capacity decreases, and they are rapidly destroyed by 
macrophages in spleen and liver. 
Enzymes activity is defected in pentosephosphate path and 
the glutathione system causes the change of lipids in the 
membrane which is incapable to resist the action of oxidizing 
agents. After taking such medication as sulfanilamides or 
antimalarial drugs, or eating fava beans (favism) such 
erythrocytes are rapidly destroyed and more often removed 
from the bloodstream (hemolysis), but intracellular hemolysis 
is also possible.  
 
Clinical picture 
HA with the presence of enzyme defects is able to devide 
into various degree of severity – from  oligosymptomatic to 
severe forms. Intracellular hemolysis prevails. The spleen is 
enlarged; in some cases the liver is enlarged too. It is often 
combined with hereditary anomaly: visual impairment, 
myasthenia, affection of the nervous system, leukopenia, and 
thrombocytopenia. 
 With the presence of defects in the enzyme system of 
pentosephosphate path, including defects in G-6-PD and 
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glutathione taking some medicine (quinine, acrichine, 
sulfonamides, and fava beans cause the development of 
hemolytic crisis with intravascular hemolysis: hemoglobinuria, 
hemosiderinuria, sometimes hemorrhagic syndrome as the 
result of thrombocytopenia and coagulation failure – 
disseminated intravascular coagulation (DIC) syndrome. 
Constant intracellular hemolysis occurs quite rarely.  
 
Laboratory Diagnosis 
In case of intravascular hemolysis (enzyme deficiencies in 
the glycolytic pathways), normochromal anemia, 
reticulocytosis, bilirubinemia, urobilinuria, stercobilin increase 
in feces, unchanged osmotic resistance of erythrocytes, 
intensified and corrected by adding glucose autohemolysis, 
intensified erythropoiesis in the myelogram are observed. 
In case of HA with intravascular haemolysis (defects of 
enzyme activity of pentosephosphate pathway and reduced 
glutathione production) hemoglobin level increases, and 
hemosiderosis of internal organs may occur. 
 
Treatment  
In most cases, when there is a constant chronic intravascular 
hemolysis, a partial effect may occur as a result of 
splenectomy. In case of enzymopathies, which are 
accompanied by glutathione restoration disturbance, taking 
flavinat (2mg 2−3 times a day) or riboflavin brings relief. 
HA with enzymopathy is incurable. To prevent hemolytic 
crisis, medications should be taken with caution. 
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1.3.2. HEREDITARY HEMOLYTIC ANEMIA CAUSED  
BY ABNORMAL HEMOGLOBIN 
DISORDERS OF HEMOGLOBIN SYNTHESIS  
This group of diseases includes HA that are associated with 
disorders in the synthesis rate of one or more polypeptide 
chains of globin (thalassemia) and HA caused by a change of 
the primary structure of polypeptide chains which results in 
stability and function disturbance of Hb (hemoglobinopathy 
with abnormal Hb). 
Hb abnormalities quite often affect inhabitants of the 
Mediterranean region, Central and East Africa, Middle East, 
South Asia and South-East Asia, and African Americans. The 
disease is also spread throughout the Caucasus, Transcaucasia, 
and Central Asia.  
 
1.3.3. THALASSEMIA 
 
Etiology  
Thalassemia is a group of inherited diseases that is 
characterized by deletion or mutation of genes that control 
globin production of hemoglobin chains. Most thalassemias are 
inherited as an autosomal recessive or dominant trait. 
 
Pathogenesis  
A globin molecule of a healthy individual consists of 2 pairs 
of polypeptide chains. Fetal hemoglobin (als. Hb F, 
hemoglobin F or 22) consists of 2 -chains and 2 -chains. 
Gradually, Hb F is nearly almost replaced by Hb of an adult – 
Hb A which is nonhomogeneous and consists of Hb A1 (97 %), 
that consists of 2 -chains and 2 - chains (22), and Hb А2 
(3 %), that consists of 2 -chains and 2 -chains (22). 
Depending on the types of globin chains that are reduced, 
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specialists distinguish - and -thalassemias. More frequent -
thalassemia is characterized by a genetic deficiency in the 
synthesis of -globin chains (the reduced β+ or absent β0 
synthesis of the β-globin chains of the globin tetramer): this 
causes the decrease in HbA1 and the increase in Hb F and Hb 
A2 levels. 
 
Clinical Picture 
Thalassemia is a HA that leads to intracellular haemolysis of 
various forms of severity (from subclinical forms to severe 
hemolysis). 
According to a severity degree, there are thalasemia major 
(homozygous – Cooley’s anemia) and thalassemia minor 
(heterozygous mediterranean anemia) -thalassemia.  
Signs of thalassemia major may be noticed in the first year 
of life; especially severe cases cause death. In case of mild HA, 
the patients can reach their puberty. A mild case of HA is 
diagnosed in the second year of life, and such patients live till 
their mature age. The typical symptoms for thalassemia major 
are paleskin, with some grayish-yellow tinge, growth inhibition 
and large size of a head (Mongoloid face and square skull as a 
result of intensified hyperplasia of bone marrow). The children 
suffer from growth retardation. X-ray examination of cranial 
bones shows thickening of plates and trabeculal of spongy 
bones in the form of a brush as a result of intensified 
hematopoiesis.  The abdomen is enlarged because of the liver 
and spleen enlargement. In case of mild homozygous -
thalassemia, cholelithiasis, hemosiderosis, trophic ulcer, 
various infections, and circulatory disturbances occur in the 
background of lingering clinical course of the disease.  
Most patients with (heterozygous) -thalassemia minor have 
a latent form of the disease and live a full life. Sometimes the 
disease is diagnosed by accident. In some cases, there is a 
marked HA with slight icterus and an enlarged spleen. The 
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signs of HA are more intense in infections or during 
pregnancy.  
Clinical signs of -thalassemia depend on the number of 
missing genes. In case of a homozygous major form provided 
the lack of 4 genes, intrauterine death of the fetus occurs 
(hydrocephalus and marked hepatosplenomegaly). Patients 
with heterozygous forms of thalassemia can suffer from 
moderate to mild HA, yellow coloring of the skin and anemia. 
Laboratory diagnosis shows typical symptoms of 
intracellular hemolysis.  
Screening test of thalassemia reviels that osmotic resistance 
of erythrocytes increases. When thalassemia is suspected, the 
type of Hb must be defined with the help of electrophoresis on 
the various carriers. In the uncertain cases, the rate of Hb chain 
synthesis, including labeled amino acids, should be examined.  
Homozygous -thalassemia is characterized by the absence 
of    HbA1 (0-thalassemia) or the decrease of its degrees (+-
thalassemia), or increase of HbF and НЬА2 degrees. 
Heterozygous -thalassemia is also characterized be moderate 
increase of НЬ F and НЬА2 degrees. In case of -thalassemia, a 
ratio between various types of Hb does not change, but the -
chain synthesis is delayed.  
Symptomatic principle is one of the thalassemia treatment 
principles. 
Repeated hemotransfusion is the basic method of treatment 
for homozygous thalassemia. To avoid sensitizing, first of all, 
washed or defrosted erythrocytes are used every 2−3 days to 
elevate Hb level. Then the treatment includes supportive 
hemotransfusion (every 3−4 weeks) untill Hb level has been 
increased to 90−100 g/l.  
This tactics is especially important in the reatment of 
children to ensure their better physical and mental 
development. 
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We should prescribe desferal to bind free iron in the 
bloodstream and enhance its elimination in the urine, because 
iron is not used in treatment of thalassemia but causes 
susceptibility to hemosiderosis of the internal organs. 
Splenectomy should be carried out in marked hypersplenism 
or in repeated splenic infarctions. 
There is no need in hemotransfusions or splenectomy in 
heterozygous - and - thalassemia. Repeated infusions of 
Desferal are required. Iron preparations are strongly 
contraindicated. Folic acid is recommended for elevation of 
erythropoiesis in pregnant women with infections. 
1.3.4. HEREDITARY HEMOLYTIC ANEMIA CAUSED 
BY STRUCTURAL FAILURE IN HEMOGLOBIN 
CHAINS 
This type of anemias includes hereditary HA caused by the 
presence of abnormal Hb as a result of substitution of one or 
more amino acids in the polypeptide chain of globin. 
Nowadays, more than 150 abnormal Hb are known. 
Substitution occurs in the -chain most often. 
 
Etiology  
Hereditary diseases occur as a result of dripping mutation in 
the genes that code the formation of globin chains most often 
are inherited according to autosomal dominant pattern.  
 
Pathogenesis  
Clinical presentations of abnormal Hb depend on the 
molecular structure and its functional changes. Generally, 
abnormal Hb are stable in homo- and heterozygote conditions, 
the pathology is not clinically evident, and abnormal Hb are 
diagnosed accidentally.  
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Sometimes, substitution of amino acids causes the change in 
the configuration of globin chains, their correlation violation 
and the change in the strength of heme attachment. Such types 
of hemoglobinopathy have certain clinical manifestations. The 
most common of them is a sickle-cell anemia or 
hemoglobinopathy S. In case of this disease, Hb A is 
substituted by Hb S (sickle-cell hemoglobin) that, in turn, 
replaces glutamic acid with valine in the -chain. As a result of 
partial pressure decrease, conditioned by hypoxia, solubility of 
Hb S solubility is almost 100 times less compared to normal 
Hb, its molecules crystallize, erythrocytes elongate and deform, 
which causes an increase in blood viscosity, and its stasis leads 
to microthrombosis, ischemia, necrosis, and fibrosis. Defective 
erythrocytes are rapidly destroyed in the spleen. That’s why an 
enlargement of the spleen is evident even in the early stages of 
the disease, and repeated splenic infarctions result in 
autosplenectomy. Furthermore, in the abnormal Hb the heme of 
iron was oxidized to form methaemoglobin, in which Hb is 
strongly combined with oxygen, and cyanosis and the 
development of polycythemia are caused by them. 
 
Clinical Picture  
A broad clinical picture in case of homozygous form of 
sickle cell anemia is revealed from the first six months of a 
child’s life, when fetal Hb has been substituted by Hb S. The 
clinical picture includes the signs of moderate HA and severe 
venous thrombosis in internal organs. Typical symptoms of 
sickle cell anemia such as fatigue, anemia, pain creses, and 
bone infarcts can occur at any age. Infants and younge children 
can suffer with fever, abdominal pain, bacterial infections, 
painfull swelling of the hands and feet, and splenic 
sequestration. Young adults develop leg ulcers, aseptic necrosis 
and eye damage. Symptoms in adults typically are intermittent 
pain episodes due to injury of bones, muscle or internal organs. 
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There is the ability of development of leg ulcers and priapism 
sometimes. Physical development and sexual maturation of a 
child are delayed. 
On the other hand, the background of complications (such as 
bacterial infections and thrombosis) in patients with 
homozygous patients with sickle cell anemia, quite often a 
hemolytic crisis with acute intravascular hemolysis, aplastic 
and hypoplastic crisis, and sequestration crisis (associated with 
a massive flow of erythrocytes from the blood stream to the 
internal organs) develop. Heterozygous sickle cell anomaly is 
characterized by the absence of clinical symptoms that appear 
only during hypoxia (e.g., pneumonia, narcosis, mountain 
climbing, or scuba diving). 
 
Laboratory Diagnosis  
Besides diagnosis of HA, sickle-cell anemia is characterized 
by the presence of sickle erythrocytes (meniscocytes). Sickle 
resemblance becomes evident in the conditions of hypoxia 
when performing some special tests (with sodium metabisulfite 
and after application of tourniquet on the finger). The character 
of hemoglobinopathy can be clarified by performing Hb 
electrophoresis. In a homozygous form of sickle cell anemia 
electrophoregram demonstrates the presence of Hb S fraction 
and absence of of Hb A fraction. The presence of Hb S and Hb 
A fractions are common to the heterozygous form of (sickle-
cell disease). 
Differential diagnosis of hemoglobinopathies is performed 
in case of liver diseases (infectious hepatitis, chronic hepatitis, 
mechanical jaundice), and other HA of hereditary and immune 
nature. Sometimes, it is necessary to carry out a differential 
diagnosis of thrombolytic complications of sickle-cell anemia 
with corresponding diseases of joints, liver, kidney etc. 
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Symptomatic treatment of sickle-cell disease includes: 
- hemotransfusion, performed in severe forms of the disease 
(transfusion of washed erythrocytes, or packed RBCs); 
- oxygenotherapy and hemodilution by alkaline saline solutions 
to reduce the number of sickled cells; 
- splenectomy in patients with hypersplenism; 
- anesthetics, sedatives, spasmolytics, hydration by saline 
solutions are indicated in vaso-occlusive; 
- anti-infective therapy, especially in pulmonry infections, 
since hypoxia increases the manifestation of the disease; 
- folic acid is indicated because of intensified ineffective 
hemopoiesis; 
- desferal − the medicine for preventive treatment of 
hemosiderosis. 
1.3.5. IMMUNE HEMOLYTIC ANEMIA 
Immune HA is a group of diseases that are caused by 
immune disorders (antibodies, antigen-primed lymphocytes) 
which is resulting from destruction of erythrocytes of a patient. 
There are 4 types of immune processes, depending on their 
nature: 
- Isoimmune HA which is caused by isoantibodies or 
autoantibodies produced on exposure to drugs, toxins or other 
antigens. Antibodies enter the body from the outside 
(hemolytic disease of a fetus or a newborn), or erythrocytes, 
against which there are isoantibodies in the patient’s body 
(with incompatible blood transfusion); 
- Transimmune HA, when anti-erythrocyte antibodies or a 
mother who sufferes from immune HA, are passively 
transported through the placenta and cause HA in the baby; 
- Heteroimmune HA types are caused either by antibodies 
against modified exogenous factors (medicines) of erythrocyte 
antigens (haptenic hemolytic anemia), or by antibodies against 
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external agents (bacteria, viruses), which react with erythrocyte 
antigens; or erythrocytes are nonspecifically injured by 
exhausted immune complexes. 
- Autoimmune hemolytic anemia (AIHA) is associated with the 
production of antibodies directed against there own unchanged 
erythrocyte antigens.  
1.3.6. AUTOIMMUNE HEMOLYTIC ANEMIA 
According to serologic diagnosis, we differentiate 4 types of 
autoantibodies and forms of AIHA, which have the following 
peculiarities of the clinical course: 
- AIHA with incomplete thermal aglutinamines; 
- warm AIHA (caused mainly by warm-reactive Ig G-
mediated extravascular hemolysis); 
- cold AIHA (usually due to complement-mediated 
intravascular hemolysis); 
- mixed type AIHA (based on the termal range of 
autoantibodies involved in the pathogenesis). 
AIHA may appear without any reason (idiopathic AIHA) or 
as a complication of another disease (symptomatic AIHA). 
Symptomatic forms of AIHA are observed in hemoblastosis, 
especially in lymphoprofilirative diseases, autoimmune 
diseases (colagenosis, nonspecific ulcerative colitis, chronic 
hepatitis etc.), malignant tumors, primary (hereditary) 
immunodeficiency and with the uses of ɑ-methyldopa. 
 
Etiology  
AIHA is a process which is associated with the loss of 
immunological tolerance to native antigens as a result of 
primary changes in the immunocompetent system (proliferation 
of genetically changed lymphoid cells, deficiency and reduced 
T cell suppressor functions, appearance of cross-reacting 
antibodies, etc.). 
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Pathogenesis   
AIHA is defined by the nature of antibodies. Incomplete 
thermal (warm) agglutinins bind to erythrocytes, changing 
permeability of the membrane for sodium ions. Spherocytosis 
with subsequent elimination of erythrocytes develops in the 
spleen. Intracellular hemolysis mechanism prevails. Thermal 
hemolysins, two-phase cold hemolysins and complete cold 
agglutinins cause destruction of erythrocytes in the 
bloodstream with intravascular haemolysis.  
 
Clinical Picture and Diagnosis of AIHA with Incomplete 
Thermal Hemolysins  
The course of the disease is quite variable, starting with 
subclinical forms (with gradual onset without subjective signs 
and anemia) and ending with acute hemolytic crisis and 
progressive shock.  
AIHA with subacute course provoked by old infections is 
the most common form. The temperature rises, joints and 
stomach are painful, the signs of anemia are accumulating 
(dizziness, abnormal pale, rapid or irregular heartbeats, and 
tachycardia). 
There are some clinical signs of HA with intracellular 
hemolysis that are defined by corresponding laboratory 
changes. Sometimes AIHA is accompanied by autoimmune 
thrombocytopenia (Fisher-Evans syndrome). 
Serological examination shows positive direct Coombs test, 
which helps to find incomplete thermal agglutinins, fixed on 
the surface of erythrocytes, but with insufficient number of 
antibodies, the test can be negative: this does not exclude the 
disagnosis of AIHA. Other immunologic disorders are possible 
(the level of immunoglobulin changes; there appear anti-
nuclear, anti-immunoglobulin, and antilymphocytic antibodies, 
rheumatoid factor, and false-positive syphilis reactions). 
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Clinical Picture and Diagnosis of Warm AIHA  
This form of HA is rarely observed. Clinical periods of 
exacerbation (with intravascular mechanism of hemolysis) 
alternate periods of remission. Hemolytic crisis is characterized 
by hyperhemoglobinemia and hemoglobinuria (dark urine, 
sometimes black), and hemosiderinuria. Thrombotic 
complications develop quite often. This form of AIHA is 
conditioned by the presence of thermal acid hemolysins that 
are fixed on the surface of erythrocytes and cause hemolysis if 
there is a complement. Antibodies are detected with the help of 
indirect Coombs test with erythrocytes treated by papain. 
 
Clinical Picture and Diagnosis of Cold AIHA (Cold 
Agglutinin Disease)  
Clinical manifestations of the disease are peripheral 
bloodstream disorders with signs of intravascular hemolysis 
caused by hypothermia. Peripheral disorders of a bloodstream 
(acrocyanosis of ears, nose, and fingers, Raynaudʼs syndrome; 
thrombosis and gangrene of fingers; and cold urticaria) are the 
result of erythrocyte agglutination in the capillaries in low 
body temperature. It ceases quickly in warm conditions. 
Usually hemolysis is not quite evident, and it is accompanied 
by hemoglobinemia. Only continuous overcooling provokes 
the crisis of hemoglobinuria. First signs of cold AIHA are 
observed when there are some difficulties in preparing 
peripheral blood smear, calculating blood corpuscle and 
determining blood group, because of autoagglutination of 
erythrocytes at room temperature. Therefore, it is possible to 
receive the results only when performing the investigation at 
37 ºС. A blood group of such paients is determined after 
washing erythrocytes with warm isotonic sodium chloride 
solution. In serological studies, complete cold agglutinins in a 
high titre are determined with the help of indirect Coombs test 
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and acid cold hemolysins which cause agglutination and 
haemolysis of erythrocytes in the presence of complement. 
 
Clinical Picture and Diagnosis of Cold AIHA Biphasic 
Hemolysin (Paroxysmal Cold Hemoglobinuria) 
The onset of the disease is acute: as the result of 
hypothermia, acute hemolytic crisis with hemoglobinuria starts, 
sometimes accompanied by Raynaud`s syndrome or urticarial 
vasculitis. Hemolysis lasts 2−3 days, that is why anemia is not 
long-lasting. Intravascular hemolysis can be caused by 
overcooling of the feet and hands in icy water. 
Serological investigation confirms the presence of biphasic 
cold hemolysins, also called Donath-Landsteiner hemolisins, 
which bind to RBCs only at cold temperatures and cause 
complement mediated hemolysis only after warming to body 
temperature.  
 
Differential Diagnosis of AIHA should be performed in liver 
diseases with jaundice, kidney diseases, and different anemias 
– dyserythropoietic and megaloblastic anemias, accompanied 
by hemolysis of erythrocytes, hereditary HA, and Marchiafava-
Micheli disease. Sometimes, there are some difficulties in 
differential diagnosis of idiopathic and secondary AIHA, 
especially if the underlying disease is considered a latent 
disease, and clinical signs of AIHA prevail. In some cases 
AIHA has been the first manifestation of the underlying 
disease for several years, and it is considered an idiopathic 
autoimmune anemia.  
 
Treatment  
The main treatment principle of AIHA is the prescription of 
glucocorticoids (prednisolone and its analogues) in large doses 
(first, 0.6−1 mg/kg per day during 2 weeks, and if there is no 
positive effect – 1.5−2 mg/kg). The dosage is gradually 
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reduced to a maintenance dose, under the control of a blood 
test.  
The smaller the dose is, the slower is the rate of lowering 
the dosage. A large dose is 5 mg per day, starting with 30 mg: 
2.5 mg during 4−5 days, then 2.5 mg during 2 weeks. 
Only 2.3% of patients treated with prednisolone show 
complete remission with normalization of blood values and 
negative markers of autoimmune hemolysis; 28% of patients 
achieve complete remission, but their immunological tests are 
positive; and 50% of patients have only temporary effect from 
treatment with prednisolone while a decrease in the dose or its 
elimination cause a relapse of the disease. That is why more 
than half of the patients need a maintenance dose of 
prednisolone (5−15 mg/day) for a long period of time.  
In conclusion, it is difficult for patients with AIHA to 
tolerate hemotransfusion; therefore, it is performed only in case 
of severe exacerbation – acute hemolytic crisis with possible 
shock development and severe anemia.  
Washed or defrosted erythrocytes should be chosen 
individually, with previously performed negative Coombs test. 
Patients with AIHAs with incomplete thermo hemolysin and 
prevalent intracellular hemolysis require a splenectomy. Young 
people, who are regularly taking a maintenance dose of 
prednisolone or have quite short remissions, need splenectomy 
first of all. There is a positive effect after surgical operation in 
60% of cases. A decrease in the frequency of crises and in 
prednisolone doses after operation is observed in 20% of 
patients. 
If there is no positive effect or there are contraindications to 
glucocorticoids and splenectomy, the doctor prescribes 
immune inhibitory therapy with 6-mercaptopurine 
(150−200 mg per day), Imuran (200−250 mg per day) or 
Cyclophosphan (400 mg per day) to reach remission with 
subsequent maintenance therapy with smaller doses. It is not 
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appropriate to indicate immune inhibitory therapy to children 
during haemolytic crisis.  
The treatment of AIHA with the help of cold antibodies has 
some peculiarities. Corticosteroids are less effective and should 
be prescribed in small doses (15−25 mg per day). 
Cyclophosphan or chlorbutin (2.5−5 mg per day) are more 
preferable medications among immune inhibitors. Splenectomy 
is not effective. Therapeutic plasmapheresis is recommended 
(at temperature 37 ºC). 
Symptomatic AIHAs in most cases are cured by treatment 
of a basic disease or by achieving a complete remission.  
To prevent a hemolytic crisis in case of cold AIHA an 
overcooling is contraindicated.  
1.3.7. ACQUIRED HEMOLYTIC ANEMIA WITH 
PREVALENT INTRAVASCULAR HEMOLYSIS 
Etiology  
Transfusion of incompatible blood, hemolytic toxicity, 
snake venom poisoning, malaria, Marchiafava-Micheli disease, 
and march hemoglobinuria are main causes of HA with 
intravascular mechanism of hemolysis. Some medicines acetic 
acid, or septic abortions provoke an acute hemolytic crisis.    
Clinical picture depends: on the rate and intensity of 
hemolysis, the causes of hemolysis and anemia severity.  
Main symptoms of hemolytic crisis are rapidly developed 
weakness, increased body temperature, dyspnea, intensive 
headache and low back pain, stomach ache, nausea, bile 
vomiting, and sometimes purgative defecation (dark-colored 
stool). The patient’s condition is serious, and tachycardia is 
evident. The skin is yellow, like a lemon, visible mucous 
membranes are pale. Specific sign of crisis is black or maroon 
colour of urine (hemoglobinuria). Sometimes oliguria and 
anuria with probable subsequent development of acute renal 
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insufficiency may occur. Sometimes hemorrhagic syndrome 
with appearance of typical skin rash – atomized petechial and 
small fruises, bleeding sickness of mucous membranes can be 
observed. Coagulation and hemostasis defects and acute renal 
insufficiency are caused by development of DIC, which is the 
result of abnormal exposure of blood to tissue thromboplastin 
or tissue factor. Tissue factor is released from the surfaces of 
cells during lysis of fibrin clots. Moderate hemolysis is not 
accompanied by acute renal insufficiency. In mild cases of 
intravascular haemolysis, it is accompanied by mild jaundice 
and insignificantly dark urine. 
 
Laboratory Diagnosis 
Beside typical changes that characterise HA with 
intravascular hemolysis, there are some changes in the blood 
coagulation system. Blood coagulation rates depend on 
acuteness and intensity of the hemolytic crisis and the 
acquisition time. At the beginning of hemolytic crisis there is a 
clear blood hypercoagulation. Then the phase of 
hypercoagulation changes to the phase of hypocoagulation with 
typical for DIC changes.  
 
Treatment 
In hemolytic crisis, during acute intravascular hemolysis, 
heparin (5.000 units intravenously) is prescribed, and then the 
introduction continues drop-by-drop (25 u/kg/hr, about 40.000 
units per day). The dose should be selected according to the 
control of prothrombin time and autocoagulation test (the 
prothrombin time must be increased twice). Rheopolyglucin 
and steroid hormones are introduced.    Plasmapheresis 
procedure should be conducted over a fixed time period. It 
involves 500−1000 mg of removing plasma and substituting by 
fresh frozen plasma and blood substitutes. If required 
plasmapheresis is conducted daily; in case of acute renal 
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failure, Prostenonum is introduced (2−5 mg in 300 ml of 
isotonic solution of sodium chloride, intravenous, drop-by-
drop, once a day). It must be repeated during 3−5 days. If there 
is no effect, hemodialysis is performed. In case of clinically 
apparent anemia, transfusion of washed RBCs with heparin 
content is indicated. 
 
1.3.8. HEMOLYTIC ANEMIA ASSOCIATED WITH 
MECHANICAL DAMAGE TO THE ERYTHROCYTE 
MEMBRANE 
 
The mechanical ingury to the erythrocyte membrane may be 
associated with prosthetic cardiac valve or membrane. The 
mechanical injury to erythrocytes may be caused by the surface 
of the prosthesis or by increased lysis in the vortices that are 
formed after prosthetics.      
HA can occur on the first day or a few days or weeks after 
surgery. The intensity of hemolysis varies within a fairy wide 
range. A moderate degree of intravascular hemolysis after 
surgery is rather common. Quite typical are morphological 
changes in erythrocytes − fragmented erythrocytes appear as 
schistocytes, often triangular, or keratocytes, i.e. helmet 
shaped. In some cases AIHA can occur as a result of 
sensitization of the human body by antigens of damaged 
erythrocytes. Hemolysis stops after elimination of the cause of 
the hemolysis (sometimes, after reoperation). 
March hemoglobinuria is a rare abnormal condition typical 
for healthy people (soldiers, athletes) after long running, 
protracted marching or heavy physical exercises. It is caused 
by repeated mechanical injury to erythrocytes in the vessels of 
hands and feet. It is assumed that close location of the 
capillaries to the surface of the foot matters. Clinical picture 
shows prevalence of moderate intravascular HA. 
Hemoglobinuria can be observed during some hours, but later 
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on it completely vanishes and can be indused throught 
repetitive mechanical motion. The patientʼs general condition 
is not violated: sometimes the patients feel moderate weakness, 
burning sensation in the heels and discomfort in the lower 
back. The temperature does not rise. Acute renal insufficiency 
is not typical. It is detected occasionally; it is benign. Such 
patients do not need treatment.  
Examples of diagnostic framing: 
1.  HA: congenital sickle-cell disease with hemolytic crisis. 
2.  HA: microspherocytic (Minkowski-Chauffard) anemia 
with hemolytic crisis. 
3.  HA: autoimmune disease with incomplete warm 
agglutinin and hemolytic crisis.  
4.  Paroxysmal hemoglobinuria (Marchiafava-Micheli 
disease) with hemolytic crisis.  
1.4. APLASTIC ANEMIA  
 
Aplastic anemia is a normocytic-normochromic anemia 
resulted from a loss of blood cell precursors, causing 
hypoplasia of the bone marrow, RBCs, WBCs, and platelets. 
Symptoms result from severe anemia, thrombocytopenia 
(petechiae, bleeding), or leukopenia (infections). To make a 
diagnosis it is necessary to identify peripheral pancytopenia 
and the absence of cell precursors in the bone marrow. Equine 
antithymocyte globulin and cyclosporine are used in treatment. 
Recombinant human erythropoietin and granulocyte-
macrophage colony-stimulating factor, and allogenic bone 
marrow transplantation may improve anemia.  
The term "aplastic anemia" usually implies a panhypoplasia 
of the bone marrow with associated leukopenia and 
thrombocytopenia. Selective hypoplasia of erythroid elements 
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is termed pure RBC aplasia. Despite the fact that both disorders 
are rare, aplastic anemia still occurs more often. 
 
Etiology 
True aplastic anemia (most common among adolescents and 
young adults) is idiopathic in about half of the cases. 
Recognized causes of aplastic anemia are chemicals (e.g, 
benzene and inorganic arsenic), radiation, and drugs (e.g, 
antineoplastic drugs, antibiotics, Nonsteroidal anti-
inflammatory drugs (NSAIDs), anticonvulsants, acetazolamide, 
gold salts, penicillamine, quinacrine). Mechanism of action is 
unknown, but selective (perhaps genetic) hypersensitivity 
turned out to be the principal. 
Fanconi`s anemia is a very rare inherited blood disorder that 
leads to the bone marrow failure (aplastic anemia), 
microcephaly, hypogonadism, and brown pigmentation of skin. 
It is occured among children with chromosome abnormalities. 
Fanconi`s anemia is sometimes inapparent until there is some 
disease (especially an acute infection or inflammatory disorder) 
that causes peripheral cytopenias.  
Pure RBC aplasia may be acute and reversible. Acute 
erythroblastopenia is a brief disappearance of RBC precursors 
from the marrow in different acute viral infections 
(particularly, human parvovirus infection (B19V)), especially 
in children. The duration of anemia is longer than that of acute 
infection.  
Chronic pure RBC aplasia is associated with hemolytic 
disorders, thymomas, autoimmune mechanisms and sometimes 
with drugs (e.g., tranquilizers, anticonvulsants), toxins (organic 
phosphates), riboflavin deficiency, and chronic lymphocytic 
leukemia. A rare congenital form, called Diamond-Blackfan 
anemia, usually occurs in infants but has been also reported in 
adults. Diamond-Blackfan anemia is associated with structural 
abnormalities such as small head size, characteristic facial 
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features, cleft palate, cleft lip, defects of the hands (mostly of 
the thumbs), as well as defects of the genetalia, urinary tract, 
eyes and heart. Sometimes, there is also short stature. 
 
Symptoms and Signs 
Although the onset of aplastic anemia is usually insidious, it 
can manifest itself over weeks or months after exposure to a 
toxin. Sometimes the disease is acute. Signs vary depending on 
the severity of pancytopenia. Symptoms and signs of anemia 
such as pale skin, petechiae, ecchymosis, and bleedings from 
the gums, into the conjunctivae, or in other tissues are caused 
by severe thrombocytopenia.  
Agranulocytosis makes people more vulnerable to picking 
up life-threatening infections. Splenomegaly is absent unless 
induced by transfusion hemosiderosis. Symptoms of pure RBC 
aplasia are usually mild and depend on the degree of anemia or 
underlying disorder. 
 
Diagnosis 
- anemic syndrome; 
- infectional syndrome; 
- hemorrhagic syndrome; 
- complete blood count (CBC); 
- bone marrow examination. 
Aplastic anemia is most common in young patients, 
especially in those with pancytopenia (e.g., WBC <1,500/μL, 
platelets <50,000/μL). Pure RBC aplasia (including Diamond-
Blackfan anemia) is suspected in patients with bony 
abnormalities and normocytic anemia but normal WBC and 
platelet counts. If either diagnosis is suspected, bone marrow 
examination is done. 
Aplastic anemia is characterized by normochromic 
normocytic (sometimes marginally macrocytic) RBCs. 
Reduction in the WBC count occurs chiefly in the 
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granulocytes. A platelet count is often less than 50,000/μL. 
Reticulocytes decrease in number or are absent. Serum iron is 
elevated. Aplastic anemia is characterized by acellular bone 
marrow. Normocytic anemia, reticulocytopenia, and elevated 
serum iron are the characteristic of pure RBC aplasia, but the 
levels of WBC and platelet counts are normal. Bone marrow 
cellularity and maturation can be normal except the conditions 
when erythroid precursors are absent. 
 
Treatment 
Equine antithymocyte globulin, corticosteroids, and 
cyclosporine are medicines for aplastic anemia treatment. 
Sometimes hematopoietic cell transplantation, cytokines, and 
surgery for thymoma are associated with RBC aplasia. 
The treatment of choice for aplastic anemia is equine 
antithymocyte globulin (ATG) diluted in 500 mL of normal 
saline 10−20 mg/kg/day intravenous infusion over 4−6 hours 
for the next 10 days. Shorter regimens are also used. About 
60% of patients respond to ATG.  
Allergic reactions and serum sickness can occur; some 
experts prescribe intradermal skin testing (to identify allergy 
reaction to equine serum) and concomitant corticosteroids 
(Prednisone 40 mg/m
2
/day as a single dose beginning from the 
7th for 10 days or until symptoms subside). Cyclosporine 
(5−10 mg/kg/po/day) is as effective as ATG and yields 
responses for about 50% of ATG failures, suggesting that its 
mechanism of action is different. Combination of ATG and 
cyclosporine is also effective. If aplastic anemia is very severe 
or failed to respond to ATG and cyclosporine, bone marrow 
transplantation, or cytokine therapy (erythropoietin, 
interleukin-3 or granulocyte-macrophage colony-stimulating 
factor) are most effective. 
Hematopoietic cell transplantation can help younger patients 
(particularly patients <30) but it requires an identical twin or 
 52 
human leukocyte antigen identical sibling. Preimplantation 
genetic diagnosis was developed to evaluate human leukocyte 
antigen compatibility of unaffected siblings. Since transfusions 
increase the risks for the subsequent transplantation, blood 
products are used only if it is essential. 
Pure RBC aplasia has been successfully managed by 
immunosuppressants (such as prednisone, cyclosporine, or 
cyclophosphamide), especially when an autoimmune disorder 
is suspected. Condition of the patients with thymoma-
associated pure RBC aplasia is improved after thymectomy. 
Furthermore, computer tomography is used to detect such 
lesion, and the surgery operation is considered. 
Section II. BLEEDING DISORDERS        
(HEMORRHAGIC DIATHESIS) 
 
Hemostasis is a dynamic process mediated by interactions 
between the platelates and coagulaion factors in the plasma and 
the vessel wall. Von Willebrand factor (vWF) is the 
glycoprotein that plays an important role in stopping the escape 
of blood from vessels, following vascular injury, works by 
mediating platelet adhesion. Platelet activation is also mediated 
through shear forces imposed by blood flow itself, particularly 
in areas where the vessel wall is damaged, and is also affected 
by the inflammatory state of the endothelium.  
The activated platelet surface provides the major 
physiologic site for coagulation factor activation, which is the 
result of further platelet activation and fibrin formation. 
Hemorrhagic diatheses are genetic and acquired diseases or 
syndromes with increased bleeding, abilities to repeated 
bleeding or hemorrage.  
Unusual or excessive bleeding include unexplained 
nosebleeds (epistaxis), excessive or prolonged menstrual blood 
loss (menorrhagia), prolonged bleeding after minor cuts or 
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trauma, easy bruising in tissues (ecchymoses) or skin (petechial 
or purpuric lesions), and unexplained gingival bleeding after 
tooth brushing. Systemic bleeding may be caused by defects in 
blood vessels (connective tissue diseases, vitamin C deficiency, 
hereditary hemorrhagic telangiectasia) or by quantitative or 
qualitative platelet disorders (thrombocytopenia and platelet 
dysfunction), or by  coagulation disorders in most cases. 
Classification of hemorrhagic diathesis: 
1. Thrombocytopenia and platelet dysfunctions: 
- idiopatic thrombocytopenic purpura (ITP); 
- thrombotic thrombocytopenic purpura (TTP); 
- hemolytic uremic syndrome (HUS); 
- thrombocytopenia due to splenic sequestration;  
- other causes of thrombocytopenia; 
- hereditary disorders of platelet function  
- coagulation disorders: 
- circulating anticoagulants; 
- disseminated intravascular coagulation (DIC); 
- hemophilia; 
- uncomon hereditary coagulation disorders; 
- bleeding due to abnormal blood vessels; 
- autoerythrocyte sensitization; 
- dysproteinemias causing vascular purpura; 
- hereditary hemorrhagic telangiectasia; 
- purpura simplex; 
- senile purpura. 
 
Thrombocytopenia and Platelet Dysfunction. 
Etiology and Pathophysiology of Thrombocytopenia 
 
Platelets are cellular fragments that function in the clotting 
system. Thrombopoetin, primarily produced in the liver as a 
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response of decreased numbers of marrow megakaryocytes and 
circulating platelets, stimulates the bone marrow to synthesize 
platelets from megakaryocytes. Platelets circulate from 7 to 10 
days. About 1⁄3 is always transiently sequestered in the spleen. 
The normal platelet count in adults ranges from 150,000 to 
450,000/μL (Tab. 7). 
Table 7 − Classification of thrombocytopenia 
Cause Condition 
Failed platelet production 
Decreased or absent 
megakaryocytes in 
the marrow  
Leukemia, aplastic anemia, paroxysmal 
nocturnal hemoglobinuria (some patients), 
myelosuppressive drugs  
Decreased platelet 
production despite 
the presence of 
megakaryocytes in 
the marrow  
Alcohol-induced thrombocytopenia, 
thrombocytopenia during megaloblastic 
anemias, human immunodeficiency virus-
associated thrombocytopenia, some 
myelodysplastic syndromes  
Platelet 
sequestration in the 
enlarged spleen  
Cirrhosis with congestive splenomegaly, 
myelofibrosis with myeloid metaplasia, 
Gaucher's disease 
Increased platelet destruction or consumption 
Immune destruction 
of platelets 
Immune thrombocytopenic purpura, also 
known as ITP, human immunodeficiency virus-
associated TTP, post-transfusion purpura, drug-
induced thrombocytopenia, neonatal 
alloimmune thrombocytopenia, connective 
tissue disorders, lymphoproliferative disorders  
Nonimmune 
destruction of 
platelets 
DIC, TTP, HUS, thrombocytopenia with acute 
respiratory distress syndrome  
   Dilution of platelets Massive blood replacement or exchange 
transfusion (decrease in viability of stored 
blood)  
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The risk of bleeding is inversely proportional to the platelet 
count. When the platelet count is less than 50,000/μL, minor 
bleeding occurs easily and the risk of major bleeding increases. 
When the platelet count is between 20,000 and 50,000/μL there 
is a predispose of bleeding with trauma, even minor trauma. 
When the count is less than 20,000/μL, excess bleeding can 
occur. Severe spontaneous bleeding can also happen when 
platelet number is less than 5000/μL. However, patients with 
platelet counts less than 10,000/μL may be asymptomatic for 
years. 
Symptoms and Signs 
Often, low platelet count does not lead to clinical problems; 
rather, they are picked up on a routine complete blood count. 
Occasionally, there may be bruising, nosebleeds and/or 
bleeding gums. Platelet disorders result in a typical bleeding 
pattern with plural petechiae on the skin, typically most evident 
on the lower extremities; scattered small ecchymosis at sites of 
minor trauma; mucosal bleeding (a nosebleed, also known as 
epistaxis, bleeding in the GI and urogenital tracts, and vaginal 
bleeding); and excessive bleeding after surgery. Heavy GI 
bleeding and bleeding into the central nervous system can be 
life threatening. However, massive bleeding into tissues (e.g., 
deep visceral hematomas or hemarthroses) does not commonly 
occur and suggests a coagulation disorder (hemophilia) 
(Tab. 8). 
Treatment 
For patients with thrombocytopenia or platelet dysfunction, 
drugs that further impair platelet function should be avoided, 
particularly aspirin and other NSAIDs.  
Patients may require platelet transfusion, but only in limited 
situations. Prophylactic transfusions are used sparingly because 
they may lose their effectiveness when it is repeated due to the 
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development of platelet alloantibodies.  
In case of platelet dysfunction or thrombocytopenia caused 
by decreased platelet production, transfusions are reserved for 
active bleeding or severe thrombocytopenia (e.g., platelet count                    
<10,000/μL). In thrombocytopenia caused by platelet 
destruction, transfusions are reserved for life-threatening or 
central nervous system bleeding. 
 
Table 8 − Peripheral blood smear in diagnosis                           
of thrombocytopenic purpura 
 
Findings Conditions 
Normal 
morphology of 
RBCs and WBCs  
   ITP 
   Gestational thrombocytopenia 
   human immunodeficiency virus-related         
thrombocytopenia 
   Drug-induced thrombocytopenia 
   Post-transfusion purpura 
RBC 
fragmentation  
TTP-HUS 
   Preeclampsia with DIC 
   Metastatic carcinoma 
WBC 
abnormalities  
Immature cells or greater number of mature 
lymphocytes in leukemia 
Markedly reduced granulocytic, megakaryocytic, 
and erythrocytic cell lines in the bone marrow in 
aplastic anemia 
Hypersegmented polymorphonuclear leukocytes 
in megaloblastic anemias  
Frequent giant 
platelets 
(approaching the 
size of RBCs)  
Bernard-Soulier syndrome and other congenital 
thrombocytopenias  
RBC 
abnormalities, 
nucleated RBCs, 
and immature 
granulocytes  
   Myelodysplasia 
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2.1. IDIOPATHIC THROMBOCYTOPENIC PURPURA 
 
ITP is a bleeding disorder caused by thrombocytopenia 
which is not associated with a systemic disease. Typically, it is 
a chronic condition in adults but it is usually acute and self-
limited in children. Spleen size is normal. Diagnosis requires 
other disorders to be excluded by selective tests.      
ITP usually results from the  development of antibodies 
directed against the structural platelet antigens 
(autoantibodies). In childhood ITP, the autoantibody can be 
triggered by binding viral antigen to megakaryocytes.    
In children, ITP often persists for 2−3 weeks after a viral 
illness, with sudden onset of purpura and, sometimes, oral and 
nasal bleeding. It is important to ascertain that the child does 
not have any other systemic illness, particularly DIC. In adults, 
ITP most commonly affects females and has an insidious onset. 
Usually, in the history of the disease, there is a viral infection 
that precedes this disease. When the disease manifests, some 
cases may be associated with symptoms or signs of a 
connective tissue disease, whilst in other patients, these 
disorders may become apparent later in a few years. The 
condition is likely to become chronic, with remissions and 
relapses. The peripheral blood film is normal, apart from a 
greatly reduced platelet number, whilst the bone marrow 
reveals an obvious increase in megakaryocytes.  
  
Symptoms, Signs, and Diagnosis: 
− Рetechiae and mucosal bleeding. The size of spleen is 
normal,  unless it is enlarged by a coexistent childhood 
viral infection.  
− ITP is suspected in patients with unexplained 
thrombocytopenia. Peripheral blood is normal except for 
a reduced number of platelets. 
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− Bone marrow should be examined if blood count or 
blood smear reveals abnormalities in addition to 
thrombocytopenia. Bone marrow examination reveals 
normal or possibly increased numbers of 
megakaryocytes in an otherwise normal marrow.  
Because of nonspecific diagnostic findings, diagnosis 
requires exclusion of other thrombocytopenic disorders 
suggested by clinical or laboratory tests.  
Human immunodeficiency virus testing is performed for 
patients at risk factors for human immunodeficiency virus 
infection, because human immunodeficiency virus-associated 
thrombocytopenia may be indistinguishable from ITP. 
Treatment  
Mild ITP does not require treatment. 
When platelet count falls below 10,000/μL, or below 
50,000/μL and hemorrhage occurs (e.g., in the digestive tract or 
in a severe nosebleed), treatment is usually begins with 
steroids. Corticosteroids (such as prednisone 1 mg/kg 
once/day) are rescue medicationes. In patients with a good 
response to the drug, the platelet count increases to normal 
within 2−6 weeks). 
Intravenous immunoglobulin (Ig) is used in life-threatening 
cases. Later, so-called steroid-sparing agents may be used. If 
all previous actions did not produce a positive result, 
splenectomy is performed, because platelets, targeted for 
destruction are often destroyed in the spleen (about 2⁄3 of these 
patients can achieve a remission).  In a child or an adult with 
ITP and life-threatening bleeding, a rapid phagocytic blockade 
is attempted by giving intravenous Ig 1 g/kg once/day for 1 to 2 
days. As a result, the platelet count increases in 2−4 days, but 
only for 2−4 weeks. 
Extreme cases are very rare, especially in children, and 
require an іmmunosuppressive treatment (chemotherapy 
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agents: cyclophosphamide, azathioprine, rituximab) to prevent 
the destruction of platelets by immune system. 
A platelet transfusion is usually not recommende, and 
usually it does not contribute to an increase in the patient's 
platelet count. This happens because of underlying 
autoimmune mechanisms that destroy the patient's platelets and 
stimulate the process of destruction of donor platelets. A 
notable exception is heavy bleeding, when platelet transfusion 
can form a platelet plug to stop bleeding very quickly.  
Thrombotic Thrombocytopenic Purpura and Hemolytic 
Uremic Syndrome  
This is a rare cause of thrombocytopenia presented by a 
variety of specialties that requires urgent management. 
Platelets become activated by thrombin and form platelet 
aggregate in the microvasculature, affecting the renal and 
cerebral circulation in particular. Excessive platelet aggregation 
is believed to occur because of unsufficient functioning of 
protease enzyme that results in the presence of ultralarge vWF. 
It can be associated with drugs, autoimmune disease, and 
infections (e.g., E. Coli). 
 
Symptoms and Signs 
Unexplained thrombocytopenia and microangiopathic 
hemolytic anemia are sufficient evidences for a presumptive 
diagnosis. 
TTP-HUS are suspected in patients with suggestive 
symptoms, thrombocytopenia, and anemia. If the disease is 
suspected, urinalysis, peripheral blood smear, reticulocyte 
count, serum lactate dehydrogenase, renal functions, serum 
bilirubin (direct and indirect), and Coombs' test are obtained. 
The proposed diagnosis − thrombocytopenia and anemia, with 
fragmented RBCs on the blood smear (helmet cells, triangular 
shaped, fragmented or greatly distorted RBCs – all these 
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changes describe microangiopathic hemolysis); evidence of 
hemolysis (decreased Hb level, polychromasia, increased 
reticulocyte count, increased lactate dehydrogenase); and 
negative direct antiglobulin (Coombs) test. 
Prognosis and Treatment 
Epidemic HUS in children caused by enterohemorrhagic 
infection usually spontaneously remites and is treated with 
supportive care. In other cases, untreated TTP-HUS is almost 
always fatal.  
However, about 85% of patients with plasma exchange 
recover completely. Plasma exchange continues daily for 
several days or  weeks until signs of disease activity disappear.  
The use of corticosteroids and antiplatelet agents (aspirin) in 
TTP is still controversial, but may be reasonable. 
Thrombocytopenia Due to Splenic Sequestration  
Increased splenic platelet sequestration can occur in various 
disorders that cause splenomegaly. Sequestration is expected in 
patients with congestive splenomegaly caused by advanced 
cirrhosis. The platelet count is usually over 30,000/μL unless 
the disorder causcing the splenomegaly also impairs platelet 
production (e.g., in myelofibrosis with myeloid metaplasia).  
Thrombocytopenia: Other Causes:  
- acute respiratory distress syndrome;  
- blood transfusions;  
- connective tissue and lymphoproliferative disorders  
- drugs-induced immunologic destruction: commonly used 
drugs that occasionally induce thrombocytopenia (aspirin, 
indometacin, gold salts methyldopa, oral antidiabetic drugs, 
penicillins,  cephalosporins, carbamazepine, rifampicin, sulfa 
preparations, dextran, heparin, and b-blockers); 
- gram-negative sepsis; 
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- human immunodeficiency virus. 
Qualitative Disorders of Platelet Function. Inherited 
Disorders of Platelet Function 
Inherited platelet function disorders are thought to be 
relatively rare, although the prevalence of mild disorders in 
platelet function is unclear, partially because of suboptimal 
testing for such disorders.  
Thrombasthenia (Glanzmann's disease) is a rare autosomal 
recessive disorder caused by a defect in the platelet 
glycoprotein IIb-IIIa complex; platelets cannot aggregate. 
Patients may experience severe mucosal bleeding (e.g., 
nosebleeds, finished only after nasal packing and transfusions 
of platelet concentrates).      
Bernard-Soulier syndrome is another rare autosomal 
recessive disorder. It impairs platelet adhesion due to the defect 
in the glycoprotein Ib-IX complex. The bleeding can be rather 
severe. Platelets are unusually large. They do not aggregate 
upon addition of ristocetin, but normally aggregate to collagen, 
and epinephrine. 
Both are inherited in an autosomal recessive fashion and 
present  bleeding symptoms in childhood. Platelet storage pool 
disorder is an autosomal dominant qualitative platelet disorder. 
This is a result of abnormalities in platelet granule formation. 
Hermansky-Pudlak syndrome also consists of inherited 
disorders of granule formation.  
Bleeding symptoms are variable in storage pool disorder, 
but often mild. The most common inherited disorders of 
platelet function are disorders that  prevent normal secretion of 
granule content. Several abnormalities have been removed at 
the molecular level, but they are probably associated with 
multiple abnormalities. They are usually described as secretion 
defects. Bleeding symptoms are usually mild. 
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Treatment 
Bleeding symptoms and prevention of bleeding in patients 
with severe dysfunction often require platelet transfusion. In 
order to limit the risk of alloimmunization one should limit 
exposure and use prestorage leukodepleted platelets for 
transfusion. Platelet disorders, associated with mild bleeding 
symptoms, often respond to desmopressin or 1-deamino-8-D-
arginine vasopressin (DDAVP). DDAVP increases plasma 
levels of factor VIII and vWF; it is not known whether it also 
has a direct effect on the function of platelets. In particular, 
with mucosal bleeding symptoms, antifibrinolytic therapy 
(epsilon-aminocaproic acid or tranexamic acid) is used alone or 
in combination with DDAVP or platelet therapy. 
Hereditary Intrinsic Platelet Disorders.  
Von Willebrand's Disease  
Von Willebrand's disease (vWD) is a hereditary deficiency 
of von Willebrand factor (vWF), which causes platelet 
dysfunction.  
vWF is synthesized and secreted by vascular endothelium to 
form part of the perivascular matrix. vWF promotes the platelet 
adhesion phase of hemostasis by binding with a receptor on the 
platelet surface membrane (glycoprotein Ib-IX), which 
connects the platelets to the vessel wall. vWF is also required 
to maintain normal plasma factor VIII levels. 
Disorders of amplification of platelet activation are the most 
common hereditary intrinsic platelet disorders and produce 
mild bleeding. They are able to be the result of decrease of 
adenosine diphosphate  in the platelet granules (storage pool 
deficiency), connected with the inability of generation of 
thromboxane A2 from arachidonic acid, or with inability of 
platelets to aggregate  thromboxane A2.  
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Symptoms and Signs  
Bleeding manifestations are mild to moderate and include 
easy bruising; bleeding from small skin cuts that may stop and 
start over hours; sometimes, increased menstrual bleeding; and 
abnormal bleeding after surgical procedures (e.g., tooth 
extraction, tonsillectomy). 
Diagnosis of Von Willebrand's Disease  
vWD is suspected in patients with bleeding disorders, 
particularly with a family history of the disorder.  
Definitive diagnosis requires measuring total plasma vWF 
antigen; vWF function, which is determined by the ability of 
plasma to support agglutination of normal platelets by 
ristocetin (ristocetin cofactor activity); and plasma factor VIII 
level.  
Treatment of Von Willebrand's Disease  
Patients are treated only if they are actively bleeding or are 
undergoing an invasive procedure (surgery, dental extraction). 
The treatment involves replacement of vWF by infusion of 
pasteurized concentrates of intermediate-purity factor VIII, 
containing the components of vWF. These concentrates are 
virally inactivated and, therefore, they do not transmit human 
immunodeficiency virus infection or hepatitis. These 
concentrates are preferable to cryoprecipitate, commonly used 
before, because they cannot cause transfusion-transmitted 
infections. 
High-purity concentrates of factor VIII are prepared by 
immunoaffinity chromatography and do not contain vWF. 
2.2. COAGULATION DISORDERS 
CAUSED BY CIRCULATING ANTICOAGULANTS 
 
Circulating anticoagulants (CA) may be defined as 
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autoantibodies that neutralize specific clotting factors in vivo 
(autoantibody against factor VIII or factor V) or inhibit 
protein-bound phospholipid in vitro. 
Antibodies bind to prothrombin-phospholipid complexes, 
inducing hypoprothrombinemia; these patients may bleed 
excessively. 
Factor VIII autoantibodies also arise occasionally in 
nonhemophilic patients, e.g., in a postpartum woman as a 
manifestation of underlying systemic autoimmune disease or in 
elderly patients without overt evidence of other underlying 
disease. The life-threatening hemorrhage can be caused by 
factor VIII anticoagulant. 
Therapy with cyclophosphamide and corticosteroids may 
suppress autoantibody production in patients without 
hemophilia.  
Disseminated Intravascular Coagulation (Coagulopathy             
or Defibrination Syndrome)  
DIC involves abnormal, excessive generation of thrombin 
and fibrin in the circulating blood. In the process, increased 
platelet aggregation and coagulation factor consumption occur. 
DIC that develops slowly (withing a few weeks or months)  
primarily causes venous thrombotic and embolic 
manifestations; DIC, that evolves rapidly (withing a few hours 
or days), primarily causes bleeding.  
Etiology and Pathophysiology of DIC 
–  complications of obstetrics, e.g., placental abruption, 
hypertonic saline-induced abortion, retained dead fetus or dead 
products of conception, or amniotic fluid embolism; 
–  infection, particularly with Gram-negative bacteria; 
–  malignancy, particularly mucin-secreting 
adenocarcinomas of the pancreas and prostate and acute 
promyelocytic leukemia; 
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–  any cause of shock; 
–  severe tissue damage from head trauma, burns, frostbite 
burns, or gunshot wounds; complications of prostate surgery; 
–  venomous snake bites with enzymes entering of 
enzymes the circulatory system, activating one or more clotting 
factors and generating thrombin, or directly converting 
fibrinogen to fibrin;  
–  profound intravascular hemolysis;  
–  aortic aneurysms or cavernous hemangiomas (Kasabach-
Merritt syndrome) associated with vessel wall damage and 
areas of blood stasis.  
Symptoms and Signs of DIC 
During a slowly evolving DIC, symptoms of venous 
thrombosis and pulmonary embolism may be present. 
In a severe, rapidly evolving DIC, skin puncture sites (e.g., 
venous or arterial punctures) bleed persistently; ecchymosis is 
formed at the site of parenteral injection; and serious GI 
bleeding may occur. Delayed dissolution of fibrin polymers by 
fibrinolysis may result in the mechanical disruption of RBCs 
and mild intravascular hemolysis (see section 
Thrombocytopenia and Platelet Dysfunction: TTP and HUS). 
Occasionally, microvascular thrombosis and hemorrhagic 
necrosis produce dysfunction and failure in multiple organs. 
Diagnosis of DIC: 
- decreased plasma fibrinogen; 
-  increased plasma D-dimer (an indication of cross-linked 
fibrin deposition and degradation); 
- thrombocytopenia, activated partial thromboplastin time 
(APTT) and less often prothrombin time (PT) may be 
minimally prolonged (results are typically reported as 
international normalized ratio); 
- the level of factor VIII decreased in DIC, because 
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thrombin-induced generation of activated protein C cause 
proteolysis of factor VIII. 
Treatment of DIC: 
- immediate correction of underlying cause is the priority 
(e.g., broad-spectrum antibiotic treatment of suspected gram-
negative sepsis, evacuation of the uterus in placental 
abruption);  
- if treatment is effective, DIC would quickly subside; if 
bleeding is severe, adjunctive therapy with clotting factor  
replacement is indicated, consisting of platelet  concentrates to 
correct thrombocytopenia; 
- cryoprecipitate for replacement of fibrinogen and factor 
VIII; 
- fresh frozen plasma for increasing the levels of other 
clotting factors and natural anticoagulants (antithrombin, 
proteins C and S).  
HEMOPHILIA 
Hemophilias are common hereditary bleeding disorders 
caused by deficiencies of one or several clotting factors such as 
VIII or IX.  
Hemophilia A (factor VIII deficiency), which affects about 
80% of hemophilic patients, and hemophilia B (factor IX 
deficiency) have identical clinical manifestations, screening 
test abnormalities, and X-linked genetic transmission. 
Hemophilia affects males almost exclusively because of 
location of the genes on the X chromosome. Daughters of 
hemophilic males are obligate carriers, but sons are not 
carriers. Each son of the carrier has a 50% chance of having 
hemophilia, and each daughter has a 50% chance of being a 
carrier. 
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Diagnosis: 
- patients with hemophilia has bleeding into tissues (e.g., 
hemarthroses, muscle hematomas, and retroperitoneal 
hemorrhage); the bleeding may delayed after trauma. Synovitis 
and arthropathy may be caused by hemarthroses; 
- family history; 
- APTT, blood clotting time, plasma recalcification time 
are prolonged, but the PT, bleeding time and platelet count are 
normal; 
- low levels of factor VIII and IX.  
Prevention and Treatment 
It is important to avoid aspirin and NSAIDs due to the risk 
of GI bleeding. Selective cyclooxygenase-2 inhibitors have 
comparable analgetic effect to traditional NSAIDs but with less 
upper a bleeding, and can be used with caution for hemophilia.  
Drugs should be given orally or IV to avoid surgical 
operations. 
Factor VIII is used to prevent bleeding in hemophilia A.  
Factor IX is used to treat hemophilia B. 
A temporary increase in the level of factor VIII may be 
caused by desmopressin (other trade names Ddavp, Stimate).  
An antifibrinolytic agent such as ε-aminocaproic acid, 
marketed Amicar (2.5 to 4 g po qid for 1 wk), or tranexamic 
acid, marketed as Cyklokapron (1.0 to 1.5 g po tid or qid for 
1 wk), should be given to prevent late bleeding after dental 
extraction or other oropharyngeal mucosal trauma (e.g., tongue 
laceration). 
2.3. BLEEDING DUE TO ABNORMAL BLOOD 
VESSELS 
 
Bleeding can be caused by platelet dysfunction, coagulation 
disorders, or damaged blood vessels. Vascular bleeding 
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disorders are caused by defects of blood vessels, typically 
producing petechiae, purpura, and bruising, but seldom leading 
to serious blood loss. Bleeding may be caused by deficiencies 
of vascular and perivascular collagen in Ehlers-Danlos 
syndrome and in other rare hereditary tissue disorders (such as 
pseudoxanthoma elasticum, osteogenesis imperfecta, and 
Marfan syndrome). Hemorrhage may be a prominent clinical 
feature of scurvy (Vitamin C deficiency) or Henoch-Schönlein 
purpura (HSP), a hypersensitivity vasculitis, most common in 
childhood. For vascular bleeding disorders, screening tests of 
hemostasis are usually normal. Diagnosis is clinical. 
Cryoglobulinemia 
Cryoglobulins are serum Igs that precipitate when plasma is 
cooled while flowing through the skin and subcutaneous tissues 
of the extremities. 
Monoclonal immunoglobulin, formed in Waldenström's 
macroglobulinemia or in multiple myeloma, occasionally 
behaves as cryoglobulins, since it may be mixed into IgM-IgG 
immune complexes formed in some chronic infections, most 
often in hepatitis C.  
Сryoglobulinemia can lead to small-vessel vasculitis, which 
can produce purpura. Cryoglobulins can be detected by 
laboratory testing. 
Hypergammaglobulinemic purpura is a vasculitic purpura 
that primarily affects women. Recurrent crops of small 
palpable purpuric lesions develop on the lower legs. These 
lesions leave small residual brown spots. Many patients have 
manifestations of an underlying immunologic disorder 
(Sjögren's syndrome). Diagnostic defection is a polyclonal 
increase in IgG (broad-based or diffuse 
hypergammaglobulinemia on serum protein electrophoresis). 
Purpura and other forms of abnormal bleeding (profuse 
epistaxis) in patients with Waldenström's macroglobulinemia 
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may be caused by hyperviscosity syndrome which is a result of 
markedly increased serum IgM concentration. 
 
VESSEL WALL ABNORMALITIES 
 
Vessel wall abnormalities may be congenital such as 
hereditary haemophilia telangiectasis, or acquired as for 
vasculitis. 
Hereditary haemorrhagic telangiectasia (Osler-Weber-
Rendu syndrome) 
Patients experience recurrent bleeding, in particular 
epistaxis, or iron deficiency associated with latent GI bleeding. 
Treatment may be difficult because of the multiple bleeding 
points, but regular iron therapy often stimulates the bone 
marrow to compensate for the blood loss. Local cautery or 
laser therapy may prevent single lesions from bleeding. A 
variety of medical therapies have been tried, but none has been 
found to be universally effective. 
 
Ehlers-Danlos Disease 
The Ehlers-Danlos disease is an inherited disorder of 
collagen synthesis of the connective tissue which is expressed 
by joint hyperextensibility, skin extensibility and tissue 
fragility such that capillaries, poorly supported by 
subcutaneous collagen and ecchymoses, are commonly visible. 
 
Hereditary Hemorrhagic Telangiectasia 
Hereditary hemorrhagic telangiectasia is a hereditary disease 
of vascular malformation that is transmitted as an autosomal 
dominant trait that affects both men and women. It is 
manifested by mucocutaneous telangiectasis and arteriovenous 
malformations.  
Lessions can affect the nasopharynx, central nervous 
system, lung, liver, spleen, GI tract, urinary tract, conjuctiva, 
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arms and fingers. 
Some patients have pulmonary arteriovenous fistulas. These 
fistulas may produce massive right-to-left shunts which may 
cause dyspnea, fatigue, cyanosis, or polycythemia. 
However, the first sign of their presence may be a brain 
abscess, transient ischemic attack, or stroke which is a result of 
infected or noninfected embolia. Cerebral or spinal 
arteriovenous malformations occur in some families and may 
cause the subarachnoid hemorrhage, seizures, or paraplegia.  
Symptoms, Signs, and Diagnosis  
The most characteristic lesions are small red-to-violet 
telangiectatic lesions on the face, lips, oral and nasal mucosa, 
and tips of the fingers and toes. Similar lesions may be present 
throughout the mucosa of the GI tract,  resulting in recurrent GI 
bleeding. 
Treatment 
Treatment can be difficult because of the multiple bleeding 
points but regular iron therapy often allows the bone marrow to 
compensate for blood loss. Local cautery or laser therapy can 
prevent single lesions or bleeding. A wide variety of medical 
therapies has been tried but none has been found to be 
universally effective. 
Treatment for most patients is supportive, but available 
telangiectasias can be cured by laser ablation.   
Arteriovenous fistulas can be treated by surgical resection or 
embolotherapy.  
2.4. HENOCH-SCHÖNLEIN PURPURA  
HSP, or anaphylactoid purpura, is a distinct, self-limited 
type of vasculitis that affects children and young adults. The 
patients have an acute inflammatory response to IgA and 
complement components in capillaries, mesangial tissues and 
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arterioles, leading to increased vascular permeability and 
localized hemorrhage. The syndrome is often preceded by an 
upper respiratory infection, commonly with streptococcal 
pharyngitis, or triggered by drug or food allergies. Purpuric 
rashes appear on the extensor surfaces of arms and legs, 
usually accompanied by polyarthralgias or arthritis, abdominal 
pain, and reccurent hematuria from focal glomerulonephritis. 
All coagulation tests are normal, but may result in impaired 
renal function. 
HSP is an immune complex vasculitis that affects primarily 
small vessels. It most commonly affects children.  
Common manifestations include palpable purpura, 
arthralgias, GI symptoms and signs, and glomerulonephritis.  
The diagnosis is clinical for children but usually warrants 
biopsy in adults. Disease is usually self-limited.  
Corticosteroids can relieve arthralgias and GI symptoms but 
do not alter the course of the disease. Progressive 
glomerulonephritis may require high-dose corticosteroids and 
cyclophosphamide.  
 
Symptoms and Signs of HSP  
The primary sign of the disease is sudden palpable purpuric 
skin rash, typically on the feet, legs, and arms and as a strip 
across the buttocks. The purpura may start as small areas of 
urticaria that become indurated and palpable. Crops of new 
lesions may appear after several days or a few weeks. Many 
patients also have fever and polyarthralgia with periarticular 
tenderness and swelling that affect ankles, knees, hips, wrists, 
and elbows. 
GI symptoms are common and include colicky abdominal 
pain, abdominal tenderness, and melena. Symptoms usually 
remit after about 4 weeks. For most patients, the disorder 
subsides without serious sequelae; however, some patients 
develop chronic renal failure.  
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Diagnosis of HSP:  
- biopsy of skin lesions; 
- the diagnosis is suspected in patients, particularly 
children, with typical skin findings. It should be confirmed by 
biopsy of skin lesions when leukocytoclastic vasculitis with 
IgA deposits in blood vessel walls is identified; 
- urine analysis should be performed. Hematuria, 
proteinuria, and RBC casts indicate renal involvement; 
- if renal function deteriorates, renal biopsy may help to 
define the prognosis. Diffuse glomerular involvement or 
crescent formation in most glomeruli predictes progressive 
renal failure. 
Treatment of HSP  
Treatment is symptomatic. Corticosteroids (prednisone 
2 mg/kg up to a total of 50 mg po once/day) may help to 
control abdominal pain and are occasionally needed to treat 
severe joint pain or renal disease. Pulse IV methylprednisolone 
followed by oral  cyclophosphamide which can be given for 
attemption to control inflammation when kidneys are severely 
affected. However, the effects of corticosteroids associated 
with renal manifestations are not clear. 
Autoerythrocyte Sensitization (Gardner-Diamond 
Syndrome)  
Autoerythrocyte sensitization is a rare disorder which is 
most common in women. It is characterized by local pain and 
burning that precede painful ecchymotic lesions, mostly on the 
extremities.  
In some women with autoerythrocyte sensitization, 
intradermal injection of 0.1 mL of autologous RBCs or RBC 
stroma may cause pain, swelling, and induration at the 
injection site.  
The diagnosis is based on the study of the site of intradermal 
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injection of autologous RBCs and a separate site of control 
injection (without RBCs) within 24−48 hours after the 
injection.  
Dysproteinemias Causing the Vascular Purpura  
Amyloidosis causes intracellular amyloid deposition within 
vessels in organs and tissues, throughout the body, which can 
increase vascular fragility and produces purpura. In some 
patients, coagulation factor X is adsorbed by amyloid fibrils 
and becomes deficient, but this is not usually the cause of 
bleeding. Periorbital purpura or a purpuric rash that developes 
in a nonthrombocytopenic patient after gentle stroking of the 
skin suggests amyloidosis. 
Purpura Simplex (Easy Bruising Syndrome)  
Purpura simplex is a condition characterized by easy 
bruising due to vascular fragility.  
Purpura simplex is very common. The cause and mechanism 
are unknown. It may represent a heterogeneous group of 
disorders. 
This disorder usually affects women. Bruises develop 
without known trauma on the thighs, buttocks, and upper arms. 
There is no abnormal bleeding in the history, but there is the 
possibility of easy bruising in family members. Serious 
bleeding does not occur. The platelet count and tests of platelet 
function, blood coagulation, and fibrinolysis are normal. 
There are no drugs for preventing bruising. The patients are  
advised to avoid aspirin that can increase their chance of 
bruising.  
Senile Purpura 
Senile purpura produces ecchymoses, and it is the result of 
increased vessel fragility due to the damage of dermal 
connective tissue, caused by to the dermis caused by chronic 
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sun exposure and aging.  
Senile purpura affects older patients who develop persistent 
dark purple ecchymoses, which are characteristically confined 
to the extensor surfaces of the hands and forearms. New lesions 
appear without known trauma, and then resolve over several 
days, leaving a brownish discoloration caused by deposits of 
hemosiderin. Discoloration lasts from weeks to months. The 
skin and subcutaneous tissue of the involved area often appear 
to be thinned and atrophic. There is no treatment for lesion 
resolution. The disorder has no serious health consequences, 
though it is cosmetically displeasing. 
Section III.   HEMOBLASTOSIS (Leukemias) 
Definition 
Leukemias are cancers of the WBCs involving bone 
marrow, circulating WBCs, and such organs as the spleen and 
lymph nodes. 
Etiology: 
- history of exposure to ionizing radiation (e.g., after 
atomic bombings of Nagasaki and Hiroshima) or chemicals 
(benzene); 
- prior therapy using certain antineoplastic drugs, 
particularly procarbazine, nitrosoureas (cyclophosphamide and 
melphalan), and epipodophyllotoxins (etoposide and 
teniposide); 
- viruses or infections agents associated with human cancer 
etiology (such as human T-lymphotropic virus I and II, and 
Epstein-Barr virus); 
- chromosomal translocations; 
- preexisting conditions that include immunodeficiency 
disorders, chronic myeloproliferative disorders, and 
chromosomal disorders (Fanconi's anemia, Bloom syndrome, 
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ataxia-telangiectasia, Down syndrome, and infantile X-linked 
agammaglobulinemia). 
3.1. LEUKEMIAS 
Pathophysiology 
Malignant transformation usually occurs at the pluripotent 
stem cell level, although sometimes it involves a committed 
stem cell with  limited capacity for differentiation. Abnormal 
proliferation, clonal expansion, and diminished apoptosis 
(programmed cell death) lead to replacement of normal blood 
elements by malignant cells.  
Clinical manifestations of leukemia are caused by 
suppression of normal blood cell formation and organ 
infiltration of leukemic cells. Inhibitory factors produced by 
leukemic cells and replacement of marrow space are able to 
suppress normal hematopoiesis, with ensuing anemia, 
thrombocytopenia, and granulocytopenia. The enlargement of 
the liver, spleen, and lymph nodes, with occasional kidney and 
gonadal involvement, are caused by organ infiltration. 
Meningeal infiltration connected with clinical features is 
associated with increasing intracranial pressure (cranial nerve 
palsies). 
Classification 
Acute leukemias consist of predominantly immature, poorly 
differentiated cells (usually blast forms); in chronic leukemias, 
blast cells are more mature. Acute leukemias are divided into 
lymphoblastic (ALL) and myeloid (AML) types, and may be 
further subdivided by the French-American-British (FAB) 
classification (Table 9). 
Chronic leukemias are described as lymphocytic (CLL) or 
myeloid (CML). 
Myelodysplastic syndromes are often referred to as 
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progressive bone marrow failure but with an insufficient 
proportion of blast cells (<30%) for making a definite 
diagnosis of AML; From 40 to 60% of MDS cases evolve into 
AML. 
A leukemoid reaction is defined as granulocytic 
leukocytosis (WBC >30,000/μL) produced by normal bone 
marrow in response to of systemic infection or cancer. 
Although there is a non-neoplastic disorder, a leukemoid 
reaction with a very high WBC count may require testing to 
distinguish it from CML. 
Table 9 – The French-American-British classification                  
of acute leukemias 
 
Leukemia 
and FAB 
Classification 
Description 
Acute Lymphoblastic Leukemia 
L1 Lymphoblasts with uniform, round nuclei and 
scant cytoplasm  
L2   More variable lymphoblasts; 
sometimes nuclei are irregular with more 
abundant cytoplasm than in L1 subtype  
L3 Lymphoblasts with finer nuclear chromatin 
and blue to deep blue cytoplasm that contains 
vacuoles  
FAB Classification of Acute Lymphoblastic Leukemia:          
L1 Subtype  
The L1 subtype is characterized by small (10−15μ) cells, 
with round, finely reticulated to coarse chromatin, some 
nuclear indentation, sparse, slightly basophilic cytoplasm, and 
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absence of nucleoli. 
L1 lymphoblasts are distinguished from normal mature 
lymphocytes by the homogeneity of their chromatin structure 
and their monotonous appearance.  
FAB Classification of Acute Lymphoblastic Leukemia:            
L2 Subtype  
The L2 subtype is characterized by medium-sized (14−18μ) 
cells with more heterogeneity in cell size. These lymphoblasts 
have fine chromatin, nuclear indentation and tight folding in 
some cells, basophilic cytoplasm, and nucleoli.  
L2 lymphoblasts are distinguished from myeloblasts by the 
variation of size, more basophilic cytoplasm, and lack of 
granules.  
FAB Classification of Acute Lymphoblastic Leukemia:     
L3 Subtype 
The L3 subtype is characterized by homogeneous, medium-
sized to large cells with round, demarcated, and finely 
punctuated chromatin, no folding, deeply basophilic and 
vacuolated cytoplasm, and nucleoli. Some apoptosis and 
fragmentation are usually seen.  
Vacuoles in the cytoplasm are not pathognomonic in L3, 
and other features (e.g., specific cytogenetic and immunologic 
characteristics) must be considered to make a definitive 
diagnosis (Table 10).  
Acute Promyelocytic Leukemia  
Acute promyelocytic leukemia is usually the most easily 
diagnosed acute myeloid leukemia because cytoplasm of the 
malignant cells is repleted with large eosinophilic granules and 
Auer rods. The nuclei are often multilobed with 
undistinguishable nucleoli and are heavily weighted with 
variably colored granules 
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Table 10 − Acute myeloid leukemia  
 
Acute Myeloid Leukemia 
M1 Acute myeloblastic leukemia without maturation of 
blasts 
 
M2 Acute myeloblastic leukemia; with maturation of 
blasts 
M3 Acute promyelocytic leukemia; with a characteristic 
pattern of heavy granulation granulation  
 
M4 Acute myelomonocytic leukemia with mixed 
myeloblastic and monocytoid morphology 
  
M5 Acute monoblastic leukemia; pure monoblastic 
morphology  
 
M6 Acute erythroleukemia, with predominantly 
immature erythroblastic morphology, sometimes 
including megaloblastic features 
 
M7 Acute megakaryoblastic leukemia; majority of cells 
are megakaryoblastic 
 
Acute Myeloid Leukemia Without Maturation                
(FAB AML-M1)  
In acute myeloid leukemia without maturation (AML-M1), 
the malignant cells differ according to their shape, but they are 
homogeneous in staining quality.  
There are nuclear chromatin with a characteristic ground-
glass texture, pale punched-out nucleoli, and a modest amount 
of cytoplasm in the blasts.  
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Myeloperoxidase cytochemistry and the presence of 
background dysplastic myeloid cells usually distinguish these 
primitive cells from lymphoblasts (Tab. 11). 
Blasts With Monocytic Differentiation  
The acute myelomonocytic leukemia, acute monoblastic 
leukemia, and acute monocytic leukemia are representatives of 
myeloid leukemias with cytologic and cytochemical features of 
monocytic differentiation, according to the World Health 
Organization classification. They correspond to acute myeloid 
leukemia (AML) FAB-M4, M5a, and M5b.  
These 3 subtypes of AML differ solely in what percentage 
of immature cells show cytochemical evidence of monocytic 
differentiation and whether those immature cells are more or 
less mature. Promonocytes − immature cells, but they retain 
some features of mature monocytes such as folded and 
convoluted nuclear contours with a moderate amount of 
vacuolated cytoplasm. Monoblast cells have an ameboid 
quality, with round to oval nuclei containing delicate 
chromatin, prominent nucleoli, and abundant cytoplasm.  
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Table 11 − Diagnosis of the common types of leukemia 
Feature Acute 
lymphobl
astic 
Leukemia 
Acute Myeloid 
Leukemia 
Chronic 
lympho-
cytic 
Leukemia 
Chronic 
Myeloid 
 Leukemia 
Peak age 
of 
incidence  
Childhood  Any age  Middle and 
old age  
Young 
adulthood  
WBC 
count  
High in  
50% 
Normal or 
low in  
50%  
High in  
60% 
Normal or low 
in  
40%  
High in  
98% 
Normal or 
low in 2% 
High in 
100%  
WBC 
differen-
tial   
count  
Many 
lympho-
blasts  
Many 
myeloblasts 
Small 
lympho-
cytes 
  
Entire 
myeloid 
series  
Anemia Severe in  
>90%  
Severe in >90% Mild in 
about 50% 
Mild in  
80%  
Platelets Low in  
>80% 
Low in  
>90% 
Low in  
20−30% 
High in  
60% 
Low in  
10% 
Lymph-
adenopathy 
Common Occasional Common Infrequent 
Spleno-
megaly 
In 60% In 50% Usual and 
moderate 
Usual and 
severe 
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Table 11 (cont.) 
 
3.1.1. ACUTE LEUKEMIA 
 
Acute leukemia occurs when hematopoietic stem cell 
undergoes a malignant transformation into a primitive, 
undifferentiated cell with an abnormal longevity. Such 
lymphocytes (ALL) or myeloid cells (AML) proliferate 
abnormally, replacing normal marrow tissue and hematopoietic 
cells, and inducing anemia, thrombocytopenia, and 
granulocytopenia. They can infiltrate various organs and sites 
such as the liver, spleen, lymph nodes, central nervous system, 
kidneys, and gonads because they are bloodborne. 
Symptoms and Signs 
Symptoms may persist for several days or weeks before 
diagnosis. 
Disrupted hematopoiesis is the cause of the most common 
present symptoms (е.g., anemia, infection, easy bruising and 
bleeding). Other present symptoms and signs (e.g., pallor, 
fatigue, fever, malaise, weight loss, tachycardia, and chest 
 Feature Acute 
lympho-
blastic 
Leukemia 
Acute 
Myeloid 
Leukemia 
Chronic 
lymphocytic 
Leukemia 
Chronic 
Myeloid 
Leukemia 
Other 
fea-
tures 
Without 
prophylaxis; 
CNS  
involvement 
CNS rare 
involvement 
is; Auer rods  
are 
sometimes 
seen in 
myeloblasts 
Occasional 
autoimmune 
hemolytic 
anemia and 
hypo-
gamma-
globulinemia 
Leukocyte 
alkaline 
phosphatase 
score is low; 
Philadelphia 
chromosome 
positive 
CML in 
>90% 
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pain) are usually nonspecific and attributable to anemia and a 
hypermetabolic state. Often, the cause of fever is not found, 
although granulocytopenia may cause a rapidly progressing 
and potentially life-threatening bacterial infection.  
Bleeding is usually manifested by petechiae, easy bruising, 
epistaxis, bleeding gums, or menstrual irregularity. Hematuria 
and GI bleeding are uncommon. 
Bone marrow and periosteal infiltration may cause bone and 
joint pain. 
Initial central nervous system involvement or leukemic 
meningitis (manifested as headaches, vomiting, irritability, 
cranial nerve palsies, seizures, and papilledema) is uncommon. 
Extramedullary infiltration by leukemic cells may cause 
lymphadenopathy, splenomegaly, hepatomegaly, and leukemia 
cutis (a raised, nonpruritic rash). 
Diagnosis: 
- CBC and peripheral smear; 
- Bone marrow examination; 
- Histochemical studies, cytogenetics, immunophenotyping, 
and molecular biology studies.  
Specific B-cells, T-cells, and myeloid-antigen monoclonal 
antibodies, together with flow cytometry are important. 
Other laboratory findings may detect hyperuricemia, 
hyperphosphatemia, hyperkaliemia or hypokaliemia, elevated 
serum hepatic transaminases or lactate dehydrogenase, 
hypoglycemia, and hypoxia. Lumbar puncture and head 
computer tomography are typically done for patients with 
central nervous system symptoms, B-cell ALL, high WBC 
count, or high lactate dehydrogenase. Chest x-ray is done to 
detect a mediastinal masses. Computer tomography, magnetic 
resonance imaging, or abdominal ultrasonography may help 
assess splenomegaly or leukemic infiltration of other organs. 
Peripheral blood smear is a basic and highly informative 
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diagnostic test; pancytopenia and peripheral blasts are the 
indicators of acute leukemia. The level of blast cells in the 
peripheral smear is 90% unless the WBC count is markedly 
decreased.  
Bone marrow examination (aspiration or needle biopsy) 
should be always done. The level of blast cells in the bone 
marrow is 20–95 and 95% in case of acute leukemia.  
The percentage of blast cells in peripheral blood should be 
determined. 
It is necessary to make the differential diagnosis of severe 
pancytopenia with the following disorders: 
-  aplastic anemia; 
-  viral infections such as infectious mononucleosis;  
-  vitamin B12 and folate deficiency.  
Prognosis 
Both ALL and AML treatment gives good results especially 
in younger patients. Prognosis is worse in infants and the 
elderly persons and in patients with hepatic or renal 
dysfunction, central nervous system involvement, 
myelodysplasia, or a high WBC count (>25,000/μL). Survival 
in untreated acute leukemia is generally 3 to 6 months. 
Prognosis varies according to karyotype. 
Treatment:  
- chemotherapy; 
- supportive care. 
Supportive care include the following activities:  
- transfusions; 
- antibiotics or antifungal drugs; 
- hydration and urine alkalinization; 
- psychologic support. 
The goal of treatment is complete remission, restoration of 
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normal blood counts and normal hematopoiesis, with less than 
5% blast cells, and elimination of the leukemic clone. Although 
basic principles of ALL and AML treatment are similar, the 
drug regimens differ.  
Transfusions 
Transfusions of platelets, RBCs, and granulocytes are 
administered to patients with bleeding, anemia, and 
neutropenia, respectively. Prophylactic platelet transfusion is 
done when platelets are less than 10,000/μL; a higher threshold 
(20,000/μL) is used for patients with the triad of fever, 
disseminated intravascular coagulation, and mucositis 
secondary to chemotherapy. Anemia (Hb<8g/dL) is treated 
with packed RBC transfusions. Granulocyte transfusions may 
help neutropenic patients with Gram-negative or other serious 
infections, but such benefit as prophylaxis is absent. 
Antimicrobial drugs are often nesessary because of the 
seriousness of infections in neutropenic and immunosuppressed 
patients, and infections can progress very quickly without usual 
early clinical manifestation. According to the results of 
appropriate studies and cultures, it is necessary to prescribe 
broad-spectrum bactericidal antibiotics that are effective 
against Gram-positive and Gram-negative organisms to both 
febrile and afebrile patients with neutrophil counts <500/μL. 
Hydration (twice the daily maintenance volume), urine 
alkalinization (pH 7 to 8), and electrolyte monitoring can 
prevent the hyperuricemia, hyperphosphatemia, and 
hyperkalemia (i.e., tumor lysis syndrome) caused by the rapid 
lysis of leukemic cells during initial therapy (particularly in 
ALL). Hyperuricemia can be minimized by giving allopurinol.   
Chronic Leukemia  
Chronic leukemia is usually manifested as abnormal 
leukocytosis with or without cytopenia in an otherwise 
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asymptomatic persons. Findings and management are different 
for chronic lymphocytic leukemia (CLL) and chronic 
myelocytic leukemia (CML). 
 
3.1.2. PATHOPHYSIOLOGY OF CHRONIC 
LYMPHOCYTIC LEUKEMIA 
There is a malignant transformation of CD5+ B cells in 98% 
of cases, with initial accumulated lymphocytes in the bone 
marrow, lymph nodes and other lymphoid tissues, eventually 
induced splenomegaly and hepatomegaly. 
Anemia, neutropenia, thrombocytopenia, and decreased 
immunoglobulin production are caused by abnormal 
hematopoiesis as a result of the progress of CLL. A lot of 
patients have hypogammaglobulinemia and impaired antibody 
response, perhaps related with increased cellular activity of  
suppressor T cells. The patients have increased susceptibility to 
autoimmune disease characterized by immunohemolytic 
anemias (usually Coombs' test–positive) or thrombocytopenia 
and a modestly increased risk of the development of other 
cancers. 
Difference Between Typical CLL and Other Chronic 
Leukemias  
The clonal neoplastic expansion of type T cells is a sign of           
2–3% of cases. This subtype (large granular lymphocytes with 
cytopenias) is characteristic for the following groups: 
- T-cell prolymphocytic leukemia; 
- leukemic phase of cutaneous T-cell lymphoma (Sezary 
syndrome); 
- hairy cell leukemia; 
- lymphoma of T-cell leukemia (leukemic changes that 
occur at the advanced stages of malignant lymphoma). 
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Symptoms and Signs 
The onset is usually insidious; CLL is often diagnosed 
incidentally during routine blood tests or through evaluation of 
asymptomatic lymphadenopathy. Symptomatic patients usually 
have nonspecific complaints of fatigue, anorexia, weight loss, 
dyspnea on exertion, or a sense of abdominal fullness 
(secondary to an enlarged spleen). Initial findings include 
generalized lymphadenopathy,  minimal-to-moderate 
hepatomegaly and splenomegaly. The progress of the disease 
can cause pallor as a result of anemia. Skin infiltration, either 
maculopapular or diffuse, can be a feature of T-cell CLL.                   
Hypogammaglobulinemia and granulocytopenia in late CLL 
can predispose to bacterial, viral, and fungal infections, 
especially pneumonia. Herpes zoster is common, and it usually 
affects the skin of the asociated dermatome. 
Diagnosis of CLL:  
- peripheral smear; 
- bone marrow examination; 
- immunophenotyping; 
- CLL is confirmed by examining the peripheral smear and 
bone marrow; the hallmark is sustained level of absolute 
peripheral  lymphocytosis (>5000/μL) and an increased level of 
lymphocytes (>30%) in the bone marrow. Differential 
diagnosis is facilitated by immunophenotyping. Other findings 
related to diagnosis may include hypogammaglobulinemia      
(<15% of cases) and rarely elevated lactate dehydrogenase. 
Only 10% of patients have moderate anemia (sometimes 
immunohemolytic), thrombocytopenia, or both symptoms. A 
monoclonal serum immunoglobulin spike of the same type can 
be found on the leukemic cell surface in 2–4% of cases (Tables 
12, 13). 
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Table 12 − Clinical Staging of Chronic Lymphocytic 
Leukemia. Rai (United States) Staging System 
 
 
Table 13 − Clinical Staging of Chronic Lymphocytic 
Leukemia. Binet (Europe) Staging System 
 
 Describtion 
Stage A Absolute lymphocytosis: the level of 
lymphocytes in blood >10,000/μL and ≥30% 
lymphocytes in the bone marrow, 
   Hb ≥10 g/dL, 
platelets ≥100,000/μL ≤ 2 enlarged areas*  
Stage B    As for stage A, but 3–5 enlarged areas* 
Stage C Hb < 10 g/dL, platelets < 100,000/μL, and 
any number of enlarged areas* 
* Enlarged areas: cervical, axillary, inguinal, hepatic, splenic, 
lymphatic  
 Description 
Stage 0 Absolute lymphocytosis: the level of lymphocytes 
in blood >10,000/μL and  ≥30%  lymphocytes in the 
bone marrow  
Stage I    Stage 0 plus enlarged lymph nodes  
Stage 
II 
Stage 0 plus hepatomegaly or splenomegaly  
Stage 
III 
   Stage 0 plus anemia with Hb<11 g/dL  
Stage 
IV 
Stage 0 plus thrombocytopenia with platelet counts 
<100,000/μL  
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Prognosis of  CLL 
The median survival for patients with B-cell CLL or its 
complications is 7−10 years. Patients with stages 0, I, II LCC 
may survive from 5 to 20 years without treatment. Patients 
with stages III or IV are more likely to die withing 3−4 years 
after confirmation of the diagnosis. Bone marrow failure is 
usually associated with short survival. Patients with CLL are 
more likely to develop a secondary cancer, especially skin 
cancer. 
Treatment of CLL:  
- symptom amelioration; 
- supportive care. 
Although CLL is progressive, some patients may be 
asymptomatic for years; therapy is not indicated until 
progression or symptoms occur. Cure usually is not possible, 
so treatment attempts to ameliorate symptoms and prolong life. 
Supportive care includes transfusion of packed RBCs or 
erythropoietin injections for anemia; platelet transfusions for 
bleeding associated with thrombocytopenia; and antimicrobial 
drugs for bacterial, fungal, or viral infections. Antibiotic 
therapy should include bactericidal activities, because patients 
with neutropenia and agammaglobulinemia are more 
predisposed to bacterial infections. Therapeutic infusions of γ-
globulin should be considered for patients with 
hypogammaglobulinemia and repeated to prevent or treat 
refractory infections for prevention as ≥ 2 types of severe 
infections can develop within 6 months. 
Types of specific therapeutic treatment: 
- chemotherapy; 
- corticosteroids; 
- monoclonal antibody therapy; 
- radiation therapy; 
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- these modalities may alleviate symptoms but have not 
been proven to prolong survival.  
Chemotherapy 
Chemotherapy is a response to the emergence of 
symptomatic disease, including constitutional symptoms (e.g., 
fever, night sweats, extreme fatigue, weight loss); significant 
hepatomegaly, splenomegaly, or lymphadenopathy; 
lymphocytosis >100,000/μL; and infections accompanied by 
anemia, neutropenia, or thrombocytopenia; alkylating agents, 
especially chlorambucil alone or combined with 
corticosteroids; 
Interferon-α, deoxycoformycin, and 2-chlorodeoxy-
adenosine are highly effective in treating hairy cell leukemia.   
Corticosteroids 
Immunohemolytic anemia and thrombocytopenia are the 
indications to prescription of corticosteroids. Prednisone 
1 mg/kg peroral daily may cause striking, rapid improvement 
in patients with advanced CLL, although the response to the 
drug is often short-term. Metabolic complications, increasing 
rate and severity of infections require long-term use of the 
drug. Prednisone in combination fludarabine leads to an 
increased risk for Pneumocystis jiroveci and Listeria infections. 
Monoclonal antibody therapy 
Rituximab, sold under the brand name Rituxan, is the first 
monoclonal antibody used in the successful treatment of 
lymphoid cancers. A partial response rate at conventional doses 
in patients with CLL is 10 to 15%. In previously untreated 
patients, the response rate is 75%, with 20% of patients 
achieving complete remission.  
Alemtuzumab, also known as Campath, has response rate of 
33% in previously treated patients who were refractory to or 
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intolerent of their lates chemotherapy.  
Fludarabine, also known as Fludara has a response rate of 
75 to 80% in previously untreated patients.  
Radiation Therapy 
Radiotherapy may be given locally to the areas of 
lymphadenopathy, sometimes with liver and spleen 
involvement, with good palliative results. Low-dose total body 
irradiation may also cure cancer or delay its progression. 
3.1.3. CHRONIC MYELOID LEUKEMIA  
(CHRONIC GRANULOCYTIC LEUKEMIA, CHRONIC 
MYELOGENOUS LEUKEMIA, CHRONIC 
MYELOCYTIC LEUKEMIA, OR NON-LYMPHOCYTIC 
LEUKEMIA) 
 
CML occurs when malignant transformation and clonal 
myeloproliferation of pluripotent stem cell, leading to a 
striking overproduction of immature granulocytes, take plase.  
CML  accounts for about 15% of all causes of adult 
leukemias. CML can strike at any age, though it is uncommon 
at the age under 10. The average age at diagnosis of CML is 45 
to 55 and it may occur in either sex. 
Pathophysiology of CML 
Most cases of CML induce translocation of the Philadelphia 
(Ph) chromosome, which is revealed in 95% of patients. It is 
characterized by a reciprocal translocation of chromosome 9 
and 22,  t (9; 22) (q34; q11), which results in the fusion of 
BCR/ABL gene. The BCR/ABL fusion gene is important in the 
pathogenesis and expression of CML and results in the 
production of a specific tyrosine kinase. CML ensues when an 
abnormal pluripotent hematopoietic progenitor cell initiates the 
excessive production of granulocytes, primarily in the bone 
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marrow but also at the extramedullary sites (spleen and liver). 
Although granulocyte production predominates, the neoplastic 
clone includes RBC, megakaryocyte, monocyte, and even some 
T and B cells. Normal stem cells are retained and they are able 
to emerge after medicines suppress the CML clone. 
CML has 3 Phases:  
- chronic phase is an initial indolent period that lasts from 
months to years; 
- accelerated myeloproliferative phase includes the 
treatment failure, the worsening anemia, and the progressive 
thrombocytopenia; 
- terminal phase includes the blast crisis, and the blast cell 
tumors with developmental capacity at the extramedullary sites 
(such as bones, the central nervous system, lymph nodes, and 
skin). 
Symptoms and Signs of CML                                                 
Patients are often asymptomatic on the early stages, with 
insidious onset of nonspecific symptoms (such as fatigue, 
weakness, anorexia, weight loss, fever, night sweats, and sense 
of abdominal fullness). Initially, pallor, bleeding, easy bruising, 
and lymphadenopathy are unusual, but moderate or suddenly 
extreme splenomegaly is common (60–70% of cases). With the 
disease progression, splenomegaly  can increase, and pallor and 
bleeding can occur. Fever, marked lymphadenopathy, and 
maculopapular skin involvement are ominous developments. 
Diagnosis of CML: 
- CBC and peripheral blood smear; 
- bone marrow examination; 
- cytogenetic studies (Ph chromosome); 
- CML is diagnosed most frequently by a CBC 
occasionally or during evaluation of splenomegaly. 
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Granulocyte count is elevated, usually <50,000/μL in 
asymptomatic patients and 200,000/μL to 1,000,000/μL in 
symptomatic patients, and platelet count is normal or 
moderately increased. Hb level is usually >10 g/dL. 
Distinguish CML from Leukocytosis of Other Etiology 
In CML, peripheral blood smear shows predominantly 
immature granulocytes and absolute eosinophilia and 
basophilia, though in patients with WBC count <50,000/μL, 
immature granulocytes can be uncommon. Leukocytosis for 
patients with myelofibrosis is usually associated with 
nucleated RBCs, tear-shaped RBCs, anemia, and 
thrombocytopenia. Myeloid leukemoid reactions are the result 
of cancer or infection; they are not associated with absolute 
eosinophilia and basophilia 
A peripheral blood smear should be taken in the chronic-
phase of CML. 
The leukocyte alkaline phosphatase score is usually low in 
CML and increased in leukemoid reactions. Bone marrow 
examination should be done to evaluate the karyotype as well 
as cellularity and the degree of myelofibrosis. 
The diagnosis is confirmed by the presence of the Ph 
chromosome in cytogenetic or molecular studies, although it is 
absent in 5% of patients. 
Accelerated phase 
During the accelerated phase of the disease, anemia and 
thrombocytopenia usually develops.  
Basophils can increase, and granulocyte maturation process 
can be defective. The proportion of immature cells and the 
leukocyte alkaline phosphatase score can increase.  
In the bone marrow, myelofibrosis can develop and 
sideroblasts can be seen in a microscop.  
Evolution of the neoplastic clone may be associated with the 
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development of new abnormal karyotypes, often an extra 
chromosome 8 or isochromosome 17. 
Terminal Phase 
Further development of the disease can lead to a blast crisis 
with the formation of myeloblasts (60% of patients), 
lymphoblasts (30%), and megakaryocytoblasts (10%). 
 Additional chromosomal abnormalities frequently occur in 
80% of these patients. 
In blast-phase CML, the percentage of blasts exceeds 30% 
in the peripheral blood or in the bone marrow. The blasts have 
dispersed chromatin, variably prominent nucleoli, and a high 
nucleus-to-cytoplasm ratio, and they are morphologically 
indistinguishable from those seen in denovo acute leukemia. 
There are myeloid, lymphoid, or multilineage phenotype 
according to the stem-cell nature of CML. Phenotype of blastic 
transformation is correlated with the secondary cytogenetic 
abnormalities acquired in the process of transformation. The 
myeloid phenotype of blasts occurs in about 70–75% of 
patients, and the leukemic cells in these patients commonly 
harbor +8, +19, +21, i(17), or (+)Philadelphia chromosome. 
The lymphoid blast phase is less common and less consistently 
associated with any particular chromosomal aberrations. 
A peripheral blood smear in blast-phase CML is necessary. 
Prognosis of CML 
With the use of imatinib mesylate (the generic equivalent 
for Gleevec (R)), >90% of patients survived withing 5 years 
after the  diagnosis. Before treatment with imatinib, from 5% to 
10% of patients died within 2 years after the diagnosis;         
10–15% died each year thereafter. Median survival was from 4 
to 7 years. Most (90%) deaths are due to the blast crisis or the 
accelerated phase of the disease. Median survival after the blast 
crisis lasts about 3−6 months, but can to increase up to 12 
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months with remission. 
Ph-negative CML and chronic myelomonocytic leukemia 
have  worse prognosis than Ph-positive CML. Their clinical 
behavior resembles myelodysplastic syndrome. 
Treatment of CML 
CML treatment includes: 
- a tyrosine kinase inhibitor, sometimes with chemotherapy; 
- sometimes, stem cell transplantation. 
Treatment is not curative for all situations except for 
unsuccessful transplantation of stem cells; however, lifetime 
after the treatment with imatinib can be extended. Imatinib and 
several new drugs are the inhibitors of the specific tyrosine 
kinase resulted from the ABL-BCR gene product. It is 
dramatically effective in achieving complete clinical and 
cytogenetic remissions of Ph-positive CML, and it is more 
effective than other regimens (interferon-α-2c and hydroxyurea 
with or without low-dose cytosine-arabinoside). Imatinib is 
more effective than other drugs in the accelerated and blast 
phases.  
Old regimens of chemotherapy are reserved for ABL-BCR–
negative patients and patients relapsed after receiving imatinib, 
and patients with blast crisis. The main agents to be used are 
busulfan (the genetic equivalent for Myleran, hydroxyurea (the 
genetic equivalent for Hydrea), and interferon-apha. 
Hydroxyurea is the easiest medicine to manage and has the 
fewest adverse effects. The starting dosage is generally 
500−1000 mg po bid. A complete blood count test should be 
done every 1−2 weeks, and the dosage should be adjusted 
accordingly.  
Allogenetic stem cell transplantation can be useful for 
refractory patients after frontline therapy. 
Although splenic radiation is rarely used, it is able to be 
helpful in refractory cases of CML or in terminal patients with 
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marked splenomegaly. Total dosage usually ranges from 6 Gy 
to 10 Gy delivered in fractions of 0.25−2 Gy/day.  
Splenectomy can alleviate the abdominal discomfort, lessen 
thrombocytopenia, and relieve transfusion requirements when 
splenomegaly cannot be controlled by chemotherapy or 
irradiation. Splenectomy does not play a significant role during 
the chronic phase of CML. 
 
Multiple Myeloma (Myelomatosis or Plasma Cell Myeloma) 
Multiple myeloma is a cancer of plasma cells which produce 
monoclonal Ig, and they can invade and destroy adjacent bone 
tissue. Bone pain, renal insufficiency, hypercalcemia, anemia, 
and recurrent infections belong to common manifestations of 
the disease.  
Diagnosis requires demonstration of M-protein (sometimes 
present in urine but not serum) and either lytic bone lesions, 
light-chain proteinuria, or excessive marrow plasma cells. A 
bone marrow biopsy is usually needed. Specific treatment 
includes conventional chemotherapy with the medication 
treatment by bortezomib, lenalidomide, thalidomide, 
corticosteroids, and high-dose melphalan followed by 
autologous peripheral blood stem cell transplantation.  
The incidence of multiple myeloma is 2 to 4/100,000. The 
male-female ratio is 1.6:1, and the median age is about 65 
years. Prevalence of multiple myeloma in the black race is 
twice that in whites. The etiology is unknown, although 
chromosomal and genetic factors, radiation, and chemicals 
have been suggested. 
 
Pathophysiology 
The M-protein produced by the malignant plasma cells is 
IgG in about 55% of myeloma patients and IgA in about 20%; 
of patients producing either IgG or IgA; 40% of myeloma 
patients also have Bence Jones proteinuria, which is free 
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monoclonal κ or λ light chains in the urine. In 15−20% of 
patients, plasma cells secrete only Bence Jones protein. IgD 
myeloma is observed approximately in 1% of cases. 
Usually we observe the development of diffuse osteoporosis 
or discrete osteolytic lesions, in the pelvis, spine, ribs, and 
skull. Lesions are caused by bone replacement, by expanding 
plasmacytomas or by cytokines that are secreted by malignant 
plasma cells which activate osteoclasts and suppress 
osteoblasts. Although the osteolytic lesions are usually 
multiple, they occasionally occur as a solitary intramedullary 
mass. Enhanced bone loss also can lead to hypercalcemia.  
Extraosseous solitary plasmacytomas are unusual but can 
occur in any tissue, especially in the upper respiratory tract. 
Renal failure (myeloma kidney) occurs in many patients with a 
diagnosis of multiple myeloma or due to many other causes, 
most commonly from deposition of light chains in the distal 
tubules and hypercalcemia (Tab. 15).  
 
Table 15 − Variants of manifestations of multiple myeloma 
Variants of  Manifestations of Multiple Myeloma 
Extramedullary 
plasmacytoma 
Plasmacytomas occur outside the medullary 
system 
Solitary 
plasmacytoma of 
the bone 
Single bone plasmacytoma, which does not 
usually produce M-protein 
Osteosclerotic 
myeloma (POEMS 
syndrome) 
Polyneuropathy (chronic inflammatory 
polyneuropathy) 
Organomegaly (hepatomegaly, splenomegaly, 
or lymphadenopathy) 
Endocrinopathy (e.g., gynecomastia, testicular 
atrophy) 
M-protein 
Skin changes (e.g., hyperpigmentation, excess 
hair) 
Nonsecretory 
myeloma 
Absence of M-protein in serum and urine 
Presence of M-protein in plasma cells 
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Along with multiple myeloma we can observe the 
development of anemia associated with kidney disease or 
suppression of erythropoiesis by cancer cells. Susceptibility of 
bacterial infection can occur in some patients. Viral infections, 
especially herpetic infections, occur more often as a result of 
increaseingly new treatment modalities. Secondary amyloidosis 
(see the section Amyloidosis: Secondary amyloidosis) occurs 
in 10% of patients with myeloma, and most often in patients 
with λ-type of Bence Jones proteinuria. 
 
Symptoms and Signs 
Persistent bone pain (especially in the back or thorax), renal 
failure, and recurrent bacterial infections are the most common 
problems that are obvious, but many patients are identified 
after showing the elevated total protein level in the blood or 
proteinuria in laboratory routine tests. Pathologic fractures are 
common, and vertebral collapse can cause the spinal cord 
compression and paraplegia. Symptoms of anemia predominate 
or may be the sole reason for determining the disease in some 
patients; and a few patients have manifestations of 
hyperviscosity syndrome (see Plasma Cell Disorders: 
Symptoms and Signs). Peripheral neuropathy, carpal tunnel 
syndrome, abnormal bleeding, and symptoms of hypercalcemia 
(eg, polydipsia) are common. Patients with renal failure may 
also have multiple myeloma. Lymphadenopathy and 
hepatosplenomegaly are unusual. 
Diagnosis: 
- CBC with platelets, peripheral blood smear, erythrocyte 
sedimentation rate, chemistry panel (blood urea 
nitrogen, creatinine, Ca, uric acid, lactate 
dehydrogenase); 
- serum and urine protein electrophoresis, followed by 
immunofixation; 
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- X-rays (skeletal survey); 
- bone marrow examination. 
Multiple myeloma is suspected in patients >40 years with 
persistent unexplained bone pain, particularly at night or at 
rest, other typical symptoms or unexplained laboratory 
abnormalities such as elevated blood protein or urinary protein, 
hypercalcemia, renal insufficiency, or anemia. Laboratory 
evaluation includes routine blood tests, protein electrophoresis, 
x-rays, and bone marrow examination. 
Routine blood tests include the CBC, erythrocyte 
sedimentation rate, and chemistry panel. Anemia is present in 
80% of patients, usually normocytic-normochromic anemia 
with rouleau formation, which are the clusters of 3 to 12 RBCs 
in stacks. WBC and platelet counts are usually normal. 
Erythrocyte sedimentation rate is usually >100 mm/h; blood 
urea nitrogen, serum creatinine, lactate dehydrogenase, and 
serum uric acid are often elevated. Anion gap is sometimes 
low. Hypercalcemia is diagnosed in about 10% of patients. 
Protein electrophoresis is done on the serum and urine 
samples concentrated from a 24-h collection to quantify the 
urinary M-protein. Serum electrophoresis identifies M-protein 
in about 80−90% of patients. Free monoclonal light chains 
(Bence Jones protein) or IgD are determined in 10−20% of 
patiens. They always have M-protein detected by urine protein 
electrophoresis. Immunofixation electrophoresis can identify 
the abnormal Ig, M-protein, and often detects light-chain 
protein if serum immunoelectrophoresis is falsely negative; 
immunofixation electrophoresis is done even if serum test is 
negative and multiple myeloma is strongly suspected. Light-
chain analysis with delineation of κ and λ ratios helps to 
confirm the diagnosis. Light-chain analysis can also be used to 
follow the efficacy of therapy and provide prognostic data. 
Serum level of β2-microglobulin is measured if the diagnosis is 
either confirmed or very likely to be confirmed; it is often 
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elevated, and albumin may be decreased. A new international 
staging system uses the levels of serum albumin and β2-
microglobulin to indicate severity of the disease and a 
subsequent prognosis. 
X-rays include a skeletal survey. Punched-out lytic lesions 
or diffuse osteoporosis is present in 80% of cases. 
Radionuclide bone scans usually are not helpful. Magnetic 
resonance imaging can provide more details and it is obtained 
if specific sites of pain or neurologic symptoms are present. 
Bone marrow aspiration and biopsy are done and reveal 
sheets or clusters of plasma cells; myeloma is diagnosed when 
>10% of the cells are of the myeloma type. However, marrow 
involvement is patchy; therefore, some samples from patients 
with myeloma may show <10% of plasma cells. Still, the 
number of marrow plasma cells is rarely normal. Plasma cell 
morphology does not correlate with the class of 
immunoglobulin synthesized. Chromosomal studies on bone 
marrow may reveal specific karyotypic abnormalities in plasma 
cells associated with differences in their survival. 
In patients without serum M protein, myeloma is indicated 
by Bence Jones proteinuria >300 mg/24 h, osteolytic lesions 
(without evidence of metastatic cancer or granulomatous 
disease), and sheets or clusters of marrow plasma cells. 
Prognosis 
The disease is progressive and incurable, but median 
survival has recently improved to >5 years as a result of 
advances in treatment. Signs of unfavorable prognosis when 
diagnosing are expressed by lower serum albumin and higher 
β2-microglobulin levels. Patients with renal failure also have 
poorly prognosis unless kidney function is  improved with 
therapy. 
Since multiple myeloma is ultimately fatal, patients should 
discuss about end-of-life care with their doctors, family, and 
 100 
friends. Points for discussion should be about advance 
directives, the use of feeding tubes, and pain relief. 
Treatment: 
- chemotherapy for symptomatic patients 
- thalidomide (trade name: Thalomid), bortezomib (trade 
name: Velcade), or lenalidomide with corticosteroids 
and/or chemotherapy; 
- possible maintenance therapy; 
- possible stem cell transplantation; 
- possible radiation therapy; 
- treatment of complications (anemia, hypercalcemia, 
renal insufficiency, infections, skeletal lesions). 
Treatment of myeloma has improved in the past decade, and 
long-term survival is a reasonable therapeutic target. Therapy 
involves the direct treatment of malignant cells for 
symptomatic patients and the treatment of complications. 
Probably the benefits of treatment are absent for asymptomatic 
patients, which is usually withheld until symptoms or 
complications develop. However, patients with lytic lesions or 
bone tissue loss (osteopenia or osteoporosis) should be treated 
with monthly infusions of zoledronic acid, called zometa, to 
reduce the risk of skeletal complications. 
Treatment of malignant cells: Until recently, conventional 
chemotherapy consisted only of oral melphalan and prednisone 
intake in cycles of 4 to 6 weeks with evaluation of response 
during months. Recent studies show superior outcome with the 
addition of either bortezomib or thalidomide. Other 
chemotherapeutic drugs, including alkylating medicines (e.g., 
cyclophosphamide, named Cytoxan; doxorubicin, named 
Adriamycin, and its newer analog pegylated liposomal 
doxorubicin, are also more effective in combination with 
thalidomide or bortezomib. A lot of other patients are 
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effectively treated by bortezomib, thalidomide, or lenalidomide 
in combination with glucocorticoids and/or chemotherapy. 
Chemotherapy response is indicated by decreases in serum 
or urine M-protein, increases in RBCs, and improvement in 
renal function in patients with kidney failure. 
Autologous peripheral blood stem cell transplantation may 
be considered for patients with adequate cardiac, hepatic, 
pulmonary, and renal functions, particularly for persons with 
stable disease or responsive one after several cycles of initial 
therapy. Allogeneic stem cell transplantation after non-
myeloablative chemotherapy (e.g., low-dose 
cyclophosphamide and fludarabine or low-dose radiation 
therapy) can provide myeloma-free survival of 5 to 10 years in 
some patients. However, allogeneic stem cell transplantation 
remains an  experimental approach in treatment because of 
high morbidity and mortality from graft vs. host disease. 
In relapsed or refractory myeloma, combinations of 
bortezomib, thalidomide, or its newer analog lenalidomide with 
chemotherapy or corticosteroids may be used. These drugs are 
usually combined with other effective drugs that the patient has 
not yet been treated with, although patients with prolonged 
remissions may respond to retreatment with the same regimen 
that led to the remission. 
Maintenance therapy has been tried with 
nonchemotherapeutic drugs, including interferon-α, which 
prolongs remission but does not improve survival and is 
associated with significant adverse effects. Following a 
response to corticosteroid-based regimens, corticosteroids 
alone are effective as a maintenance treatment. Thalidomide 
may also be effective as a maintenance treatment, and studies 
are evaluating maintenance therapy with bortezomib and 
lenalidomide among patients with responsivity to these drugs 
prescribed alone or in combination therapeutic regimens. 
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Treatment of complications: In addition to treatment of 
malignant cells, therapy must also be directed at complications 
such as anemia, hypercalcemia, renal insufficiency, infections, 
and skeletal lesions. 
Anemia can be treated with recombinant erythropoietin 
(40,000 units sc q wk) in patients whose anemia is 
inadequately relieved by chemotherapy. If there are 
cardiovascular or significant systemic symptoms after anemia, 
packed RBCs are transfused. Plasmapheresis is indicated if 
there is the development of hyperviscosity (see Plasma Cell 
Disorders: Symptoms and Signs). 
Hypercalcemia is treated by saluresis, IV bisphosphonates, 
and sometimes with Prednisone. Most patients do not require 
Allopurinol. However, Allopurinol is prescribed for patients 
with high levels of serum uric acid or high tumor burden and a 
high risk of tumor lysis syndrome after treatment. 
Renal compromise can be improved by adequate hydration. 
Even patients with prolonged, massive Bence Jones proteinuria 
(≥10−30 g/day) can have intact renal function if they maintain 
urine output >2000 mL/day. Acute oliguric renal failure in 
patients with Bence Jones proteinuria may be caused by the 
combination of dehydration and high osmolar contrast media 
i.v. 
The infection is more likely to happen during 
chemotherapy-induced neutropenia. In addition, infections with 
herpes zoster virus occur more frequently in patients treated 
with new antimyeloma drugs. Documented bacterial infections 
should be treated with antibiotics; however, preventive use of 
antibiotics is not routinely recommended. Preventive use of 
antiviral drugs may be indicated for patients who receive 
specific drugs. Preventive IV Ig can reduce the risk of 
infection, but it is commonly reserved for patients with 
recurring infections. Pneumococcal and influenza vaccines are 
indicated to prevent the infection. 
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Skeletal lesions require multiple supportive measures. 
Prescription of ambulation and supplemental Ca and vitamin D 
helps to preserve the density of bones. Analgesics and 
palliative doses of radiation therapy (18−24 Gy) can alleviate 
bone pain. However, radiation therapy is prescribed to impaire 
the patient's ability for receiving the cytotoxic doses of 
systemic chemotherapy. Receiving a monthly i.v. 
bisphosphonates (either Pamidronate or zoledronic acid) is 
necessary for patients, especially with lytic lesions and 
generalized osteoporosis or osteopenia. Skeletal complications 
and bone pain are reduced by bisphosphonates with antitumor 
effect. 
Introduction (Dysproteinemias. Monoclonal 
Gammopathies. Paraproteinemias. Plasma Cell Dyscrasias) 
Plasma cell disorders are the diverse group of disorders with 
unknown etiology characterized by the disproportionate 
proliferation of one clone of B cells and the presence of a 
structurally and electrophoretically homogeneous (monoclonal) 
Ig or polypeptide subunit in serum, urine, or both. 
Pathophysiology 
For structural features and classification of the Ig, see 
Biology of the Immune System: Antibodies. 
After the development in the bone marrow, undifferentiated 
B cells enter the peripheral lymphoid tissues, such as lymph 
nodes, the spleen, the gut, and Peyer's patches. Here, they 
begin to differentiate into cells, each being able to respond the 
limited number of antigens. There is a clonal proliferation of 
some B cells into plasma cells after connection with the 
appropriate antigen. Each clonal plasma cell line is committed 
to synthesize one specific Ig antibody that consists of 2 
identical heavy chains (gamma [γ], mu [μ], alpha [α], delta [δ], 
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or epsilon [ε]) and 2 identical light chains (kappa [κ] or lambda 
[λ]). A slight excess of light chains is normally produced, and 
urinary excretion of small amounts of free polyclonal light 
chains (≤40 mg/24 h) is normal. 
The etiology of plasma cell disorders is unknown and they 
are characterized by the disproportionate proliferation of one 
clone. The result is a corresponding increase in the serum level 
of its product, the monoclonal Ig protein (M-protein). 
M-proteins may consist of both heavy and light chains or of 
only one type of chain. Some of them show the antibody’s 
activity with ability to produce an autoimmune damage of 
organs, particularly kidneys. When M-proteins are produced, 
production of other Ig is commonly reduced, and immunity 
may become impaired. M-protein can cover the platelets, 
inactivate clotting factors, increase blood viscosity, and cause 
bleeding. M-proteins can also produce secondary amyloidosis. 
The clonal cells can infiltrate bone matrix or marrow, with the 
resultant osteoporosis, hypercalcemia, anemia, or 
pancytopenia. 
Plasma cell disorders may vary from asymptomatic, stable 
conditions (in which only protein is present) to progressive 
cancers (e.g., multiple myeloma: to classify plasma cell 
disorders, see Table 1). Sometimes, transient plasma cell 
disorders are typical for patients with drug hypersensitivity 
(sulfonamide, phenytoin and penicillin), with presumed viral 
infections, and after cardiac or transplant surgery.  
Plasma cell disorders may be suspected because of clinical 
manifestations, findings during evaluation of anemia, or an 
incidental finding of elevated serum protein or proteinuria that 
caused further evaluation with serum or urine protein 
electrophoresis. There is a way of determining M-protein, 
which is further evaluated by immunofixation electrophoresis 
to identify heavy and light chain classes. 
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Macroglobulinemia (Primary Macroglobulinemia. 
Waldenström's Macroglobulinemia) 
Macroglobulinemia is a malignant plasma cell disorder 
which causes the production of excessive amounts of IgM M-
proteins by B cells. The disease manifests itself in 
hyperviscosity, bleeding, recurring infections, and generalized 
adenopathy. Diagnosis requires bone marrow examination and 
demonstration of M-protein. Treatment includes 
plasmapheresis as needed for hyperviscosity, and systemic 
therapy with alkylating drugs, corticosteroids, nucleoside 
analogs, or monoclonal antibodies.  
Macroglobulinemia, an uncommon B-cell cancer, is 
clinically more similar to a lymphomatous disease than to 
myeloma and other plasma cell disorders. The cause is 
unknown. Men are affected more often than women; the 
median age is 65. 
Macroglobulinemia is the second most common malignant 
disorder associated with a monoclonal gammopathy after 
myeloma. Excessive amounts of IgM M-proteins can also 
accumulate in other disorders and cause manifestations similar 
to macroglobulinemia. Small monoclonal IgM components are 
present in the serum of about 5% of patients with B-cell non-
Hodgkin lymphoma; this circumstance is termed 
macroglobulinemic lymphoma. Moreover, IgM M-proteins are 
occasionally present in patients with chronic lymphocytic 
leukemia or other lymphoproliferative disorders. 
Clinical manifestations of macroglobulinemia may be 
caused by a large amount of high molecular weight monoclonal 
IgM proteins circulated in plasma, but most patients do not 
have problems related to high IgM levels. Some of these 
proteins are antibodies directed toward autologous IgG 
(rheumatoid factors) or I antigens (cold agglutinins). About 
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10% of them are cryoglobulins. Secondary amyloidosis occurs 
in 5% of patients. 
 
Symptoms and Signs 
Most patients have asymptomatic disease, but many patients 
have signs of hyperviscosity syndrome, including fatigue, 
weakness, skin and mucosal bleeding, visual disturbances, 
headache, symptoms of peripheral neuropathy, and other 
neurologic manifestations. An increased plasma volume can 
precipitate the heart failure. Cold sensitivity, Raynaud's 
syndrome, or recurring bacterial infections may appear. 
A complete examination can reveal lymphadenopathy, 
hepatosplenomegaly, and purpura. Marked engorgement and 
localized narrowing of retinal veins, which resemble sausage 
links, suggests hyperviscosity syndrome. Retinal hemorrhages, 
exudates, microaneurysms, and papilledema appear in the late 
stages. 
 
Diagnosis: 
- CBC with platelets, RBC indices, peripheral blood smear; 
- serum protein electrophoresis, followed by serum and urine 
immunofixation; 
- serum viscosity assay; 
- bone marrow examination; 
- sometimes, lymph node biopsy. 
Macroglobulinemia is suspected in patients with symptoms 
of hyperviscosity or other typical symptoms, particularly, if 
anemia is present. However, it is often diagnosed accidentally, 
when protein electrophoresis reveals M-protein that proves to 
be IgM by immunofixation. The laboratory examination 
includes tests to evaluate plasma cell disorders (see Plasma 
Cell Disorders: Multiple Myeloma) as well as measurement of 
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cryoglobulins, rheumatoid factor, cold agglutinins, coagulation 
studies, and the direct Coombs test. 
A moderate normocytic normochromic anemia, marked 
rouleaux formation, and a very high erythrocyte sedimentation 
rate are typical. Leukopenia, relative lymphocytosis, and 
thrombocytopenia occur occasionally. Cryoglobulins, 
rheumatoid factor, or cold agglutinins may be present. If cold 
agglutinins are present, the direct Coombs test is usually 
positive. The appearance of various coagulation and platelet 
function abnormalities is possible. Results of routine blood 
studies may be spurious if cryoglobulinemia or marked 
hyperviscosity are present. Normal Ig are decreased in half of 
patients. 
Immunofixation electrophoresis of concentrated urine often 
shows a monoclonal light chain (usually κ), but gross Bence 
Jones proteinuria is unusual. Bone marrow studies show a 
variable increase of plasma cells, lymphocytes, plasmacytoid 
lymphocytes, and mast cells. Periodic acid-Schiff-positive 
material may be present in lymphoid cells. Lymph node 
biopsy, done if bone marrow examination is normal, is 
frequently interpreted as a diffuse well-differentiated or 
plasmacytic lymphocytic lymphoma. Serum viscosity is 
measured to confirm of suspected hyperviscosity, and when > 
4.0 (normal, 1.4 to 1.8) is usually present. 
 
Treatment: 
- plasmapheresis (when hyperviscosity is present); 
- alkylating drugs, nucleoside analogues, monoclonal 
antibodies (Rituximab), or their combination; 
- possible use of Bortezomib, Thalidomide, or Lenalidomide; 
- the course is variable, with the median survival of patients 
from 7 to 10 years. The age is more than 60 years; anemia and 
cryoglobulinemia are precursors of a smaller survival rate. 
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Often, the patients are not treated for many years. If they 
have hyperviscosity, the initial treatment includes 
plasmapheresis, with rapid reverse of bleeding as well as 
neurologic abnormalities. Plasmapheresis must be repeated. 
Long-term treatment with oral alkylating drugs may be 
indicated for palliation, but bone marrow toxicity can occur. 
Nucleoside analogs (Fludarabine and 2-Chlorodeoxyadenosine) 
are response products in large numbers in newly diagnosed 
patients. Rituximab can reduce tumor burden without 
suppressing normal hematopoiesis. However, during the first 
several months, IgM levels may increase, requiring 
plasmapheresis. The proteasome inhibitor, called Bortezomib, 
and the immunomodulating agents Thalidomide and 
Lenalidomide are also effective against this cancer. 
Syndrome of Disseminated Intravascular Coagulation 
(DIC) 
 
DIC is one of the most common acquired coagulopathies. It 
belongs to a leading contributor in the pathogenesis of some 
diseases. DIC can complicate various pathological processes, 
and it is often the cause of an immediate death. DIC may 
occurre in any doctor’s clinical practice of all specialties, but it 
is often not diagnosed or diagnosed too late. 
It appears as a result of involvement of a lot of factors in the 
pathological process, which activates coagulation and platelet 
aggregation with the subsequent generalized formation of 
microclots and microcirculation disorders in organs and tissues, 
which reduce the extreme degenerative changes. 
Hypocoagulation, thrombocytopenia and bleeding, caused by 
consumption coagulopathy, develop simultaneously with the 
fibrin-embolism. 
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Etiology 
There are such forms of DIC according to their cause of 
development: 
- infectional and septic (occur in septic conditions and 
generalized infection); 
- posttraumatic (occurs during crash syndrome or burn 
disease, multiple bone fractures); 
- shock-producing (various types of shock); 
- surgical (after operations with large tissue trauma); 
- obstetric (premature detachment of placenta, supply of 
amniotic fluid into the blood, septic abortion, severy course of 
toxicosis and pyelonephritis in pregnant women); 
- toxigenic (after snake bite); 
- tumor (as a result of malignant tumor growth, especially 
hemoblastosis; 
- allergic (as a result of immune and immunocomplex 
diseases) 
- caused by massive blood transfusion and transfusion of 
incompatible blood; 
- caused by destructive processes in the liver, pancreas, and 
kidneys; 
- caused by systemic diseases of connective tissue and other 
immunocomplex diseases (glomerulonephritis, etc.). 
 
Pathogenesis 
Pathogenesis of DIC is based on "a humoral explosion of 
proteases", which is a simultaneous activation of all plasma 
proteolytic enzymes that belong to the four extracellular 
biochemical systems: 
1. Blood clotting system 
2. Fibrinolytic system 
3. Kallikrein-kinin system 
4. System of complement. 
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The formation of active proteolytic blood enzymes has such 
peculiarities as: 
- possible autoactivation of enzymes means that active 
enzyme converts inactive form into an active one by acting on 
an inactive form; 
- activation of active proteases by other active proteases 
(cross-activation); 
- chain character of the activation reaction. In theory, the 
presence of only one molecule of active protease can activate 
the residue of proteases in the blood. However, a proteolytic 
activation is limited in healthy people and is associated with 
the presence of a large group of protease inhibitors. Chain 
character of the reaction activating the proteolytic systems in 
blood plasma is associated with insufficient production of 
protease inhibitors to neutralize a large number of active 
proteases, entering the blood. Such an activation of a general 
nature involves all the blood proteases and is called "humoral 
protease explosion". 
There are three main sources of proteases in the blood: 
1. The acute damage to a large number of cells which 
stimulates the entering of lysosomal proteases and tissue 
thromboplastin into the blood. 
2. The entering of a large number of extracellular proteases 
into the blood (e.g., trypsin during acute pancreatitis and 
enzymes of amniotic fluid). 
3. The entering of exogenous proteases of bacterial cells into 
the blood in patients with sepsis and poisonous snakes. 
There are two phases of pathogenesis of DIC: 
 
Phase I is called the phase of hypercoagulation and platelet 
aggregation. This phase is based on the total activation of the 
coagulation system, i.e, thrombin generation which leads to 
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fibrin clot formation and platelet aggregation. There are the 
following starting mechanisms for this phase: 
- enzymatic mechanism, associated with the entering of a 
large number of active proteases and tissue thromboplastin into 
the blood; 
- contact mechanism, associated with the activation of XII 
coagulation factor during its contact with the foreign body 
surfaces (extracorporeal dialysis, hemodialysis, artificial heart 
valves); 
- platelet mechanism, associated with the primary activation 
of platelet aggregation during total endothelial damage to blood 
vessels, abnormal blood rheology, and acute intravascular 
hemolysis of erythrocytes. 
The result of these mechanisms realization is the formation 
of a large number of micro clots and aggregates of cells, with 
subsequent microcirculation disorders and sludge syndrome 
development. 
 
Phase II is the phase of hypocoagulation (hemorrhagic 
syndrome). This phase is the result of mechanism’s depletion 
of vascular-platelet and coagulation homeostasis. It is 
characterized by the following important factors: 
- reduction of blood coagulation activity (factors II, V, VIII); 
- activation of the fibrinolytic system (by derecting a flow of 
a large number of fibrinolysis activators into the blood); 
- increased anticoagulation activity due to the formation of 
fibrinolysis blood products; 
- development of the consumption thrombocytopenia; 
- increase vascular permeability of vascular (as a result of the 
formation a large number of kinins). 
 
Classifications: 
1. According to the ICD – 10 International Classification of 
Diseases: the disease code 65 D. 
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2. Classification by V. G. Lychova (1998): 
1) according to the etiology (septic, obstetric, traumatic, 
immunocomplex, etc.); 
2)  according  to the course of the disease (immediate, acute, 
subacute, chronic, recurrent, and latent); 
3) according  to stages (phases): 
- stage I is the stage of hypercoagulation and platelet 
aggregation; 
- stage II is the intermediat phase of increased coagulopathy 
and thrombocytopenia, multidirectional shifts in coagulation 
tests; 
- stage III is the phase of deep hypocoagulation (complete 
absence of coagulation); 
- renovation (during a mild course of the complication phase). 
3. Clinical and pathogenetic variants: 
1) strong predominance of fibrinolysis and hemorrhagic 
syndrome; 
2) strong manifestation of coagulation, depressed 
fibrinolysis and symptoms of venouse thrombosis and 
thromboembolism; 
3)  acute dysfunctions of internal organs on the background 
of moderate hemorrhages with activation of coagulation and 
weakened anticoagulation; 
4)  predominant activation of cellular hemostasis, peripheral 
blood sequestration with the blockage of microcirculation, 
decrease in blood pressure and circulating blood volume; 
5)  predominant activation of hemostasis system by immune 
complexes, cryoglobulins, and toxins in capillaries lesions,  
microvascular thrombohemorrhages, and skin necrosis on the 
background of bleeding. 
 
Clinical course 
Acute period of DIC lasts hours, rarely − days. It is a result 
of shocks of different etiologies, prenatal waters embolism, 
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premature separation of placenta, acute intravascular 
hemolysis, complications after surgical operations with 
extracorporeal circulation, septicemia, and many other 
pathological processes. 
Subacute period of DIC lasts days, weeks, and months. It is 
observed after malignant tumors, myeloid leucosis, especially 
acute promyelocyte leucosis, kollagenozes, allergic vasculitis, 
amyloidosis, liver cirrhosis, uremia, viral and bacterial 
infections, and intrauterine fetal death in obstetric practice. 
Chronic period of DIC lasts months and years. It is observed 
in giant hemangioma (Kasabah-Meryta syndrome), massive 
cavernosus degeneration of blood vessels (e.g., portal system), 
etc. There are no symptoms with the latent form. It can be 
diagnosed only by laboratory tests. 
The clinical forms of DIC are defined schematically because 
of their transition. For example, the latent form with long 
duration can be converted into an acute form. 
The clinical picture depends mainly on the course of the 
main disease and the course of DIC. The phase of 
hypercoagulation is characterized by sudden coagulation or 
mixed shock, collapse, and an acute decrease in arterial and 
central venous pressures. There are also symptoms of the main 
disease. The blockage of pulmonary capillaries is the cause of 
dyspnea (called "shock lung"). The death can be caused by 
acute pulmonary heart in the most difficult cases. The damage 
to the central nervous system is characterized by intermittent 
convulsions, symptoms of small-throat encephalopathy and 
coma. The duration of this phase is different for different 
diseases. It is short for obstetrical and surgical diseases, 
longer − for therapeutic illnesses, and latent − for shocks. 
There is no clinical manifestation of hypercoagulation phase in 
the last two cases. 
The phase of hypocoagulation with different severity of 
hemorrhagic syndrome becomes after the phase of 
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hypercoagulation. Phase I is often invisible: there is only 
hemorrhagic syndrome, complicated by a particular process or 
a disease. Hemorrhagic syndrome is characterized by different 
kinds of hemorrhages, ecchymosis, and large hematomas, or 
bleeding at the sites of palpation. There is also bleeding from 
mucous membranes (of the nose, uterine, and gums). A severe 
course is characterized by generalized massive hemorrhage, 
renal hemorrhage, bleeding from the digestive tract, bleeding in 
the internal organs and in the central nervous system, profuse 
bleeding from the genital system after delivery, and bleeding 
from operative injury and stitches after surgical operation. 
The acute posthemorrhagic anemia with loss of blood is 
developed as a result of bleeding. Its severity depends on the 
amount of the lost blood. The symptoms of hypovolemia and 
metabolic disorders are also expressed. There is the 
transformation of coagulation shock into hemorrhagic shock. 
Further more, there is the development of anatomical and 
functional disorders in organs and systems such as acute 
insufficiency of adrenalglands, parenchymal dystrophy of the 
liver, liver and spleen insufficiency, small-throat 
encephalopathy as a result of fibrin embolism and blockage of 
microcirculation. Such changes appear in kidneys, even when 
DIC syndrome is mild. Oliguria and mild azotemia are 
developing. Massive DIC syndrome is characterized by 
necrosis and uremia.   
Hemorrhages and necroses are focused in the area of 
occlusive vessels. Ulcers are determined in digestive tract. In 
some cases, blood clots of fibrin can be detected only when 
examined by microscope.  We can see them with the help of 
specific fixation and coloration. The absence of clots does not 
deny DIC syndrome, because they can be dissolved by 
secondary fibrinolysis or proteolytic leukocytic enzymes. 
The clinics of subacute and chronic forms of DIC syndrome 
differ from that one of an acute form. The symptoms of the 
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basic disease appear first. The variability of clinical 
manifestations depends on the main disease. 
The general condition of the patient deteriorates rapidly. 
The collapse and hemorrhages on the skin are common 
manifestations. Such course of DIC syndrome is observed in 
other diseases. Thrombosis and thrombophlebitis are clinical 
characteristics of other diseases such as malignant tumors. It 
can be the single symptom of DIC syndrome for a long time. In 
these cases the bleeding of different intensity is the clinical 
manifestation of the hypocoagulation phase. The bleeding after 
tooth extraction or surgical operation is common.  
The chronic forms can be characterized by the latent course 
of the disease. The use of procoagulative medicines for 
intravascular coagulation is compensated by their increased 
synthesis in such cases.  
Laboratory diagnosis. The laboratory diagnosis of DIC 
syndrome is difficult to establish because the results of 
research depend on the form, stage, and severity of the disease, 
time of investigations, and the stage of disorders in coagulate 
hemostasis. 
The acute period. There is the decrease in time of blood 
coagulation, partial time of tromboplastin, time of 
recalcification of plasma, time of heparin in blood analysis for 
hypercoagulation because of trombinemia. The signs of 
hypercoagulation are defined. According to the results of 
thromboelastography, the presence of chronometric and 
structural blood hypercoagulation and the increase in adhesion 
and aggregation for platelets are determined. The activation of 
the fibrinolysis system, the products of fibrin degradation 
products (FDPs), positive tests with ethanol and protamine 
sulfate are determined. The quantity of platelets and 
antithrombin III is decreased. Sometimes the collection of 
blood is impossible because of coagulation in the needle. 
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Hypocoagulation is the next phase after hypercoagulation. 
The multidirectional general coagulation tests and 
thrombocytopenia are defined in transitional period. The blood 
clot (Lee-White sample) can appear quickly and timely, but it 
is small and reacts quickly in hypofibrinogenemia. The time of 
blood coagulation, recalcification of plasma and heparin is 
increased. This is hypocoagulation. The significant increase of 
prothrombin time is common for DIC syndrome. The 
prothrombin time of plasma is increased as a result of using 
factors of prothrombin complex. Thrombocytopenia is the 
constant attribute of DIC-syndrome. The reduction of the 
content of fibrinogen and other procoagulants (called 
thrombocytopenia and coagulopathy after consumption) is 
possible. The characteristic of this phase are rapid fibrinolysis, 
FDPs, soluble complexes of fibrin-monomers, positive tests 
with ethanol and protamine sulfate. There is determined 
blocked fibrinogen in the serum with the help of ephah-poison 
(serum coagulation test with ephah-poison) and the positive 
test of adhesion for staphylococcus. There is the decrease in the 
levels of antithrombin III and plasminogen in serum as a result 
of exhaustion of physiological anticoagulants and components 
of fibrinolitic system. The morphologically changed 
erythrocytes, microspherocytosis, shizocytosis (the 
characteristic signs of DIC) are determined in the blood smear. 
The blood is not coagulated even after addition of thrombin in 
severe cases.  
The Lee-White sample is used in urgent cases (especially in 
obstetrics) to confirm hypocoagulation phase if the main 
laboratory is not available. It is necessary to take 3−4 ml of 
blood in the test-tube and put it into water bath. The 
temperature should be +37°С. The blood from birth canal is not 
used. Normally the compact clot is defined in 5−9 minutes. The 
clot is formed in a timely manner in hypofibrinogenemia, but it 
is small, soft and soluble for strong fibrinolysis with quickly 
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reaction. There is no coagulation of blood during full blockage 
of fibrinogen. The absence of blood coagulation after thrombin 
addition is the direct confirmation of the diagnosis. 
Subacute course. The characteristic sign of subacute course 
of DIC syndrome is the gradual increase of coagulation 
disorders (days and months). The informative coagulation tests 
for acute and subacute periods are similar. 
The long coagulation, clinically characterized by 
thromboembolia, is possible for weak course of DIC-
syndrome. The laboratory data at this stage are the reduced 
rates of all coagulation tests, high sudden aggregation of 
thrombocytes, accelerated fibrinolysis, high levels of FDPs, and 
positive tests of coagulation. At this stage, there are the 
development of significant hypocoagulation and changes, 
characterized by consumption coagulopathy such as reduced 
level of fibrinogen and other procoagulation drugs, increased 
level of FDPs, positive tests with ethanol and protamine sulfate, 
positive serum coagulation sample with ephah-poison, and 
adhesion for staphylococcus. Antitrombin 3 level is decreased. 
Shizocytes are defined in the peripheral blood smear. 
The course of chronic disease lasts months and years. 
Sometimes the level of fibrinogen, factors of prothrombin 
complex and other procoagulation substances, and number of 
thrombocytes are normal or even increased for latent and 
chronic forms of DIC syndrome, which is a result of 
hyperproduction of these components after theit large 
consumption. The laboratory confirms DIC syndrome by 
detection of FDPs, fibrin-monomers and dicrease in the half-
fragmentation period of fibrinogen (1−2 days; normal duration 
is 4 days).  
The diagnostic standards: V. A. Likhachev (1993−1998) 
developed a diagnostic algorithm of DIC. All symptoms of 
illness are grouped in three classes, presented in Table 15: 
Class A (initial clinical situation, factors and pathology); Class 
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B (the most typical clinical symptoms of DIC); Class C 
(laboratory indicators).  
 
Table 15 −  Comon signs and symptoms of DIC. Class A  
 
Group 
number 
Initial clinical situation Measure 
of trust 
1  - all types of shock: stages II-III; 
 - HUS; 
 - sepsis; 
 - acute intravascular hemolysis; 
 - massive pulmonary embolism; 
 - acute hepato-renal insufficiency; 
 - crush-syndrome; 
 -  burns: stages II-III (burns >35%            
of the body); 
 - amniotic fluid embolism; 
 - acute promyelocytic leukemia; 
 - severe intoxication by snake’s poison; 
 - massive destruction of organs; 
0.95 
2  - hemorrhagic necrotizing pancreatitis; 
 - pulmonary gangrene due                           
to Staphylococcus aureus; 
 - eclampsia; 
 - other types of obstetric pathology; 
 - infant respiratory distress syndrome; 
 - drug-induced necrotic purpura; 
 - intensive hemolysis; 
 -heart insufficiency and combined 
insufficiency of heart and lungs with 
intensive development; 
- severe forms of radiation and 
cytostatic      disease; 
0.8 
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Table 15 (cont.) 
Group 
number 
Initial clinical situation Measure 
of trust 
3 - hemoblastosis; 
- malignant tumors; 
- postoperative traumas of glandular and 
parenchymal organs; 
- fractures of bones and politrauma; 
- 2
nd
 and 3
rd
 degree burns and frostbite  
(<35% of the body); 
- placenta abruption, intrauterine fetal 
death; 
- cystic mole; 
- infectiousl and toxic diseases; 
- system vasculitis; 
- macrofocal myocardial heart attack; 
(excluding severe cardiogenic shock); 
- congestive heart failure; 
- Kasabach-Merritt syndrome; 
0.7 
4 - other pathological processes which are 
not included in the groups № 1−3. But 
the measure of trust can increase in the 
group № 4 if there is the combination 
with the groups № 2 or № 3 
0.30– 
0.50 
 Clinical signs 
- acute respiratory, adrenal insufficiencies 
or renal failure; 
- combined insufficiency of two and 
more of organs described above; 
- local bleeding; 
- multiple hemorrhages of different 
localization; 
- local thrombosis or heart attack; 
- the combination of thrombosis (heart 
attack) with bleeding; 
 
0.60 
 
0.95 
 
0.40 
0.72 
 
0.35 
0.90 
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Table 15 (cont.) 
Group 
number 
Initial clinical situation Measure 
of trust 
 - collapse; 
- lasting recurrent shock, with 
hemorrhages; 
- other symptoms; 
- absence of clinical symptoms 
 
0.55 
0.95 
0.20 
0.10 
     
Every symptom has a corresponding measure of trust, 
experimentally calculated by Shortlif’s formula (from 0 to 1) 
(Tab. 16). 
 
Table 16 – Common Signs of DIC: Class C 
Laboratory tests 
 
Measure 
of trust 
- the number of platelets in the blood <130 109/l  
or  >450109/l; 
- hypo- or hypercoagulation (PT>20 s or <14 s, 
thrombin time >16 or <14 s, APTT >45 or <35 s; 
- multidirectional indicators of coagulation tests 
(PT, APTT); 
- the absence of blood coagulation according to 
the Lee-White test; 
- increased content of plasma soluble fibrin-
monomeric complexes and FDPs; 
- reduced levels of antithrombin III to <70 %; 
- raised plasma concentration of platelet factor 4 
(PF-4) or β-trombohlobulin (labialization of 
platelets); 
- damage to erythrocytes (light fraction of 
erythrocytes in verografin sodium solution in the 
blood).  
0.50 
 
0.85 
 
0.85 
 
0.95 
 
0.78 
 
0.50 
0.70 
 
 
0.80 
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The possibility of DIC is calculated by the formula of                  
V. G. Lykhachev, 1998: 
             
The sum of the characteristics of classes A and B (or Х0) =  
= МD (А) + МD(В) ∙ (1-МD(А)); 
МDgen = Х0 + (1 – Х0) ∙ МD(С). 
 
The risk of developing DIC is the highest for highest levels of 
MDgen. 
The differential diagnosis of DIC is made with congenital 
afibrinogenemia, hypofibrinogenemia caused by serious 
disorders in liver’s parenchyma and primary fibrinolysis. 
Anamnesis and laboratory analysis are very important for 
diagnosis of two primary forms. It is necessary to remember 
that liver diseases are often complicated by DIC. The number 
of platelets does not reduce in hereditary hypo- and 
afibrinogenemia and hereditary hyperfibrinolysis. 
 
Principles of treatment 
The treatment regimen depends on the disease severity. 
The therapeutic diet is table №15. 
Medical treatment: The treatment of DIC depends mainly on its 
cause, forms, and stages. 
The first stage of treatment is to liquidate cause of the 
diseases assosiated with DIC such as obstetric complications, 
massive antibiotic therapy of sepsis, surgical treatment of 
tumors, etc. 
The treatment of shock (treatment of acute DIC): 
- infusion of blood substitutes (salt solutions, Rheopolyglucin, 
and albumin) with high doses of glucocorticoids 
(hydrocortisone 1000−1500 mg/day; prednisolone 60 mg/day; 
dexamethasone 150−200 mg/day). The daily dose of 
glucocorticoids can be taken at once in severe cases (pulse 
therapy). 
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N.B. The introduction of anticoagulants eliminates the action 
of glucocorticoids associated with stimulation of blood 
coagulation; 
- the infusion of 1 ml of 0.2% solution of norepinephrine 
together with 500 ml of isotonic solution or Ringer's solution 
with the rate of 10−15 drops per minute is indicated only in 
case of anaphylactic and/or exotoxic shock; in other cases, 
preference is given to dopamin (dopamine)- biological 
precursor of norepinephrine. 200 mg (5 ml) dopamine are 
dissolved in 400 ml of Rheopolyglucin or 5% glucose solution, 
administered intravenously with an initial rate of 
2−4 mcg/kg/min with a gradual increase up to 10 mcg/kg/min. 
Dopamine delates blood vessels of the kidneys, stimulates the 
contractility of the myocardium, increases blood pressure. It 
does not increase coagulation and platelet aggregation such as 
norepinephrine. 
Heparin is a drug of choice with anticoagulant effect, 
associated with activation of such natural anticoagulant as 
antithrombin III, in the hypercoagulation phase and chronic 
form of DIC. If the content of antithrombin III is reduced − 
heparin will not be effective. The large doses of heparin lead to 
a rapid depletion of antithrombin III, which is a result of 
rebound hypercoagulation. Therefore, we should use heparin 
with drugs that include antithrombin III (fresh frozen or fresh 
native plasma). Heparin is quickly outputted for intravenous 
infusion; therefore, it is recommended to use the technique of 
infusion through the pump with constant rate during the day or 
by subcutaneous injection in the abdomen 3−4 times a day 
(half-life is extended on account of prolonged absorption from 
the subcutaneous depot). The most common are such methods 
of introduction of heparin: 
- firstly we use intravenous bolus of 10,000 IU, then 
1000−500 IU per hour drip up to 20,000 IU per day; 
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- firstly we use intravenous bolus of 10,000 IU, then − under 
the skin of the abdomen 5000 IU every 6−8 hours. 
 
Remember:  
Heparin can increase thrombocytopenia, which is associated 
with a decrease of functionally active platelets in the blood 
flow. Careful monitoring of blood platelets during heparin 
therapy is necessary. 
One of the main methods of DIC treatment at all its stages is 
administration of fresh frozen plasma (from one group). The 
fresh frozen plasma is slowly warmed to 37 °C; bolus is 
injected at a dose of 600−800 ml, and then every 6−8 h at a 
dose of    300−400 ml. Fresh frozen plasma contains all the 
necessary components for correction of hemostasis disorders 
(procoagulant, antithrombin III, protein C, components of the 
fibrinolytic system, physiological antiplatelet agents). 
Transfusion of cryoplasma helps to restore antiproteinase 
activity and to compensate the volume of the circulation fluid. 
If cryoplasma is not available, we should inject fresh plasma, 
but its effectiveness is lower. We should start to infuse plasma 
during the phase of hypercoagulation. It is combined with 
heparin, which is prescribed before each infusion of plasma 
intravenously, 2500−5000 IU (the dose is 5000–7500 IU for 
severe hypercoagulation) to activate antithrombin III. In this 
case heparin can be entered directly into the vial of plasma. 
The slow infusion of cryoplasma is not effective. 
The early administration of the following drugs to improve 
microcirculation is very important: curantyl (0.1 g 3 times a 
day orally), trental (0.1 g in 250−500 ml of 5% glucose 
solution intravenously for 1.5−2 hours) without expressed 
atherosclerosis, and ticlid (0.3 g 3 times a day orally). The 
prescription of acetylsalicylic acid is not advisable because of 
the risk of severe gastrointestinal bleeding. 
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The treatment of DIC in the intermediate phase and in the 
phase of hypercoagulation is the same, but the dose of heparin 
may be reduced according with the indicators of coagulation. 
The use of heparin is not recommended in phase of 
hypocoagulation, severe thrombocytopenia and bleeding, but 
some physicians prescribe small doses of heparin (2,500 IU) 
before blood or plasma transfusion in this case.   
Firstly, drugs to reduce the blockage of the microcirculation 
such as rheopolyglucin, dipyridamole, aminophylline, and 
papaverine are prescribed. We should administer cryoplasma as 
soon as possible. At the same time we should prescribe drugs 
to eliminate of all types of proteolysis – broad-spectrum 
protease inhibitors (trasylol, contrycal and others). These drugs 
inhibit fibrinolysis and other types of proteolysis, and also 
activate the kallikrein-kinin system, not stabilizing fibrin in 
microcirculation. They are prescribed in high doses. Therefore, 
contrycal is administered intravenously at a dose of 
50,000−100,000 IU. Then injection of the drug is repeated and 
its daily dose can be increased up to 500,000 IU and more. In 
some literature, there are recommendations to administer 
aminocapronic acid. However, aminocaproic acid inhibits only 
fibrinolysis, not affecting other types of proteolysis. 
Aminocaproic acid stimulates the blokage of fibrin in small 
vessels. Furthermore, fibrin is not exposed to fibrinolysis. As a 
result it causes serious damages in parenchymal organs. 
Therefore, the administration of aminocaproic acid in DIC is 
questionable. 
Due to the fact that the main drugs for therapy of DIC 
(cryoplasma or native fresh plasma) are not always available, 
particularly at the regional hospitals, correctional therapy of 
hemostasis can be performed by administration of dry lyophilic 
plasma frozen in the first hours after blood collection. This 
plasma is injected if it is concentrated (diluted in 1/3 volume of 
solvent specified on the label), the bolus dose is 
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1,000−1,500 ml (based on plasma dose indicated on the bottle) 
and more. There are fibrinogen and other procoagulants, which 
fill the lost protein in the dry plasma. Administration of 
cryoprecipitate and other drugs, called procoagulants, is not 
necessary because of the absence of antithrombin III. 
It is necessary to underline the ineffectiveness and dangers 
of fibrinogen prescription. Firstly, it is an unbalanced drug in 
the system of hemostasis (there is no sufficient quantity of 
another procoagulant such as antithrombin III). Secondly, 
administration of fibrinogen with large amount of FDPs is 
dangerous, because fibrinogen may be block with these 
products in fibrin-monomeric complexes. It leads to blockage 
of microcirculation. 
Platelet transfusion or platelet concentrate is prescribed for 
profuse bleeding in acute thrombocytopenia. 
The replenishment of lost blood and treatment of anemia are 
important. If the volume of blood loss is less than 
800−1000 ml, the best thing to do is to administrate of 
rheopolyglucin and other blood substitutes. The replacement of 
RBCs is necessary in severe blood loss. Freshly prepared 
(immediately before transfusion) "warm" citrated blood is the 
drug of choice in massive blood loss. You can also transfuse 
erythrocyte mass or the washed fresh erythrocytes. Introduction 
of preserved blood during 3 days or more is not prescribed 
because of blood clots that enhance DIC. Reinfusion of blood 
from the body cavity of a patient contraindicated in DIC 
because its the risk of developing syndrome. 
The normalization of red blood indexes is not necessary, 
because of promotion of DIC ("syndrome of massive 
transfusion, homological blood syndrome") by massive blood 
transfusion, caused the circulatory overload, agglutination of 
red blood cells. 
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If the levels of erythrocytes and hematocrit are higher than         
2,51012/l and 22%, respectively, the replenishment of blood is 
required. 
It is necessary to account the amount of transfused fluid 
because its large volume can cause pulmonary edema. Lasix 
and osmotic diuretics are prescribed in this situation. The 
patient should receive mechanical ventilation with positive 
pressure in the lungs during exhalation. 
Plasmapheresis is used for subacute and chronic forms of 
DIC, especially for inflectional and septic DIC, for toxic forms, 
and immunоcomplex pathologies. During one procedure 
doctors remove 500−1000 ml of plasma, replacing it by fresh 
frozen plasma and blood substitute. The number of procedures 
is determined by the cause of disease. Dopamine is injected in 
acute insufficiency of kidneys (intravenously, in 0.05% 
solution with 5 % glucose solution at a rate of 5−10 drops per 1 
min; the daily dose of dopamine is 200−400 mg). Forced 
diuresis, transfusion of fresh frozen plasma are also prescribed 
for acute insufficiency of kidneys. 
Professor G. M. Glants of Lviv Institute of Hematology and 
Blood Transfusion has developed an original method of 
treatment for acute renal failure, associated with prostin E2 
(prostaglandin E) administration. Prostin E2 is administered 
intravenously, slowly (2−5 mg prostin E2 in 300 ml of isotonic 
solution of sodium chloride) 1 time a day. The infusion of the 
drug is repeated withing 3−5 days, depending on the severity of 
acute renal failure. Hemodialysis is prescribed in case of 
ineffectiveness of such treatment. 
DIC prevention depends on qualified timely treatment to 
prevent the development of this syndrome and in rejection of 
unjustified transfusions of preserved blood in large volumes. 
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Abbreviations 
AIHA – autoimmune hemolytic anemia  
ALL – acute lymphoblastic leukemia 
AML – acute myeloid leukemia 
ATG – antithymocyte globulin  
CA – circulating anticoagulants  
CBC – complete blood count 
CLL – chronic lymphocytic leukemia 
CML – chronic myeloid leukemia 
DDAVP – 1-deamino-8-D-arginine vasopressin 
DIC – disseminated intravascular coagulation 
DNA – deoxyribonucleic acid 
FAB – French-American-British 
GI – gastrointestinal bleeding 
G-6-PD – glucose 6 phosphate dehydrogenase  
H – hypochromia 
HA – hemolytic anemias 
Hb – hemoglobin  
HSP – Henoch-Schonlein purpura 
HUS – hemolytic-uremic syndrome  
IDA – iron deficiency anemia 
ICD-10 – International Classification of Diseases, 10th Rev. 
ITP – idiopatic thrombocytopenic purpura 
Ig – immunoglobulin 
M – microcytosis  
MCV – mean corpuscular volume 
MCHC – mean the corpuscular hemoglobin concentration 
NSAIDs – nonsteroidal anti-inflammatory drugs 
PA –  pernicious anemias 
FDPs – fibrin degradation products 
PT – prothrombin time 
RBCs/WBCs – red/white blood cells 
TTP – thrombotic thrombocytopenic purpura 
vWF/vWD – von Willebrand factor/disease 
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